===== SIDA 1 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 1 29 July 2025 AstraZeneca results: H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and EPS summary H1 2025 % Change Q2 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11 Reported EPS ($) 3.46 31 32 1.58 27 31 Core3 EPS ($) 4.66 16 17 2.17 10 12 Key performance elements for H1 2025 (Growth numbers at constant exchange rates)  Total Revenue up 11% to $28,045m, driven by double-digit growth in Oncology and BioPharmaceuticals  Growth in Total Revenue across all major geographic regions  Core Operating profit increased 13%  Core EPS increased 17% to $4.66  12 positive Phase III readouts and 19 approvals in major regions  Interim dividend increased 3% to $1.03 (76.7 pence, 9.81 SEK) Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readouts including for baxdrostat, gefurulimab, and Tagrisso in just the past few weeks. As we enter our next phase of growth, we have pledged $50 billion to continue to grow in the US, which includes the largest manufacturing investment in AstraZeneca’s history, set for Virginia. This landmark investment reflects not only America’s importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca’s ambition to deliver $80 billion revenue by 2030.” Guidance AstraZeneca reiterates its Total Revenue and Core EPS guidance4 for FY 2025 at CER, based on the average foreign exchange rates through 2024. Total Revenue is expected to increase by a high single-digit percentage Core EPS is expected to increase by a low double-digit percentage The Core Tax rate is expected to be between 18-22% If foreign exchange rates for July 2025 to December 2025 were to remain at the average rates seen in June 2025, it is anticipated that FY 2025 Total Revenue growth and Core EPS growth would be broadly similar to the growth at CER (previously a low single-digit percentage adverse impact was anticipated) ===== SIDA 2 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 2 Navigation tips To navigate to a section or table, click the hyperlinked titles in this contents page, and in header at the top of every page. To return to the previous location after using a hyperlink, press + (Windows) or + (MacOS) Example: - To see the definition of an acronym, click ‘Glossary’ at the top right of the page. - After reading the definition, press + or + to return to the previous location. Contents Results highlights ...................................................................................................................................................................................... 3 Revenue drivers ........................................................................................................................................................................................ 6 R&D progress .......................................................................................................................................................................................... 11 Sustainability .......................................................................................................................................................................................... 15 Operating and financial review............................................................................................................................................................... 16 Financial performance ............................................................................................................................................................................ 17 Interim financial statements................................................................................................................................................................... 23 Responsibility statement of the directors in respect of the half-yearly financial report ........................................................................ 28 Independent review report to AstraZeneca PLC .................................................................................................................................... 29 Notes to the Interim financial statements.............................................................................................................................................. 30 Other shareholder information .............................................................................................................................................................. 40 Glossary .................................................................................................................................................................................................. 42 Tables Table 1. Milestones achieved since the prior results announcement ...................................................................................................... 3 Table 2: Key elements of financial performance: Q2 2025 ....................................................................................................................... 4 Table 3: Product Revenue by medicine .................................................................................................................................................... 6 Table 4: Collaboration Revenue................................................................................................................................................................ 7 Table 5: Total Revenue by Therapy Area .................................................................................................................................................. 7 Table 6: Total Revenue by region ............................................................................................................................................................. 7 Table 7: Reported Profit and Loss ........................................................................................................................................................... 17 Table 8: Reconciliation of Reported Profit before tax to EBITDA ........................................................................................................... 17 Table 9: Reconciliation of Reported to Core financial measures: H1 2025 ............................................................................................ 17 Table 10: Reconciliation of Reported to Core financial measures: Q2 2025 .......................................................................................... 18 Table 11: Cash Flow summary: H1 2025 ................................................................................................................................................. 19 Table 12: Net debt summary .................................................................................................................................................................. 19 Table 13: Obligor group summarised Statement of comprehensive income: H1 2025 .......................................................................... 20 Table 14: Obligor group summarised Statement of financial position ................................................................................................... 20 Table 15: Currency sensitivities .............................................................................................................................................................. 21 Table 16: Condensed consolidated statement of comprehensive income: H1 2025 ............................................................................. 23 Table 17: Condensed consolidated statement of comprehensive income: Q2 2025 ............................................................................. 24 Table 18: Condensed consolidated statement of financial position....................................................................................................... 25 Table 19: Condensed consolidated statement of changes in equity ...................................................................................................... 26 Table 20: Condensed consolidated statement of cash flows: H1 2025 .................................................................................................. 27 Table 21: Net debt .................................................................................................................................................................................. 31 Table 22: Contingent consideration ....................................................................................................................................................... 32 Table 23: Product Sales year-on-year analysis: H1 2025 ........................................................................................................................ 37 Table 24: Product Sales year-on-year analysis: Q2 2025 (Unreviewed) ................................................................................................. 38 Table 25: Alliance Revenue: H1 2025 ..................................................................................................................................................... 39 Table 26: Collaboration Revenue: H1 2025 ............................................................................................................................................ 39 Table 27: Other operating income and expense: H1 2025 ..................................................................................................................... 39 ===== SIDA 3 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 3 Table 1. Milestones achieved since the prior results announcement Phase III and other registrational data readouts Medicine Trial Indication Event Enhertu DESTINY-Breast11 High-risk HER2+ early breast cancer (neoadjuvant) Primary endpoint met Imfinzi POTOMAC High-risk non-muscle invasive bladder cancer Primary endpoint met Tagrisso FLAURA2 1L EGFRm NSCLC Secondary endpoint met (OS) baxdrostat BaxHTN Uncontrolled or treatment resistant hypertension Primary endpoint met Breztri KALOS/LOGOS Uncontrolled asthma Primary endpoint met Fasenra NATRON HES Primary endpoint met Saphnelo AZALEA SLE (China) Primary endpoint met anselamimab CARES (301/2) Light chain amyloidosis Primary endpoint not met gefurulimab PREVAIL Generalised myasthenia gravis Primary endpoint met Regulatory approvals Medicine Trial Indication Region Calquence ECHO 1L MCL EU Calquence ACE-LY-004 Relapsed/refractory MCL EU Calquence AMPLIFY 1L CLL (fixed duration) EU Datroway TROPION-Lung05/ TROPION-Lung01 2L+ EGFRm NSCLC US Imfinzi ADRIATIC Limited-stage SCLC CN Imfinzi NIAGARA MIBC EU Tagrisso LAURA Locally advanced/unresectable EGFRm NSCLC JP Orpathys + Tagrisso SACHI Locally advanced/metastatic 2L+ EGFRm MET+ NSCLC CN Regulatory submissions or acceptances* in major regions Medicine Trial Indication Region Calquence AMPLIFY 1L CLL (fixed duration) US Enhertu DESTINY-PanTumor02 2L+ unresectable / metastatic HER2+ solid tumours JP Enhertu DESTINY-Gastric04 2L HER2+ gastric cancer CN, JP Imfinzi MATTERHORN Resectable early-stage gastric and GEJ cancers US camizestrant SERENA-6 ESR1m HR+ HER2- aBC US, EU, JP * US, EU and China regulatory submissions denotes filing acceptance Other pipeline updates For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on www.astrazeneca.com/investor-relations.html. Results highlights ===== SIDA 4 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 4 Table 2: Key elements of financial performance: Q2 2025 For the quarter Reported Change Core Change ended 30 June $m Act CER $m Act CER Product Revenue 14,449 12 11 14,449 12 11  See Tables 3, 23, 24 and 25 for medicine details of Product Revenue, Product Sales and Alliance Revenue Collaboration Revenue 8 >2x >2x 8 >2x >2x  See Tables 4 and 26 for details of Collaboration Revenue Total Revenue 14,457 12 11 14,457 12 11  See Tables 5 and 6 for Total Revenue by Therapy Area and by region Gross Margin (%) 83 - - 82 (1pp) - − Growth of partnered medicines  Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue  See ‘Reporting changes’ below for the definition of Gross Margin5 R&D expense 3,548 18 16 3,453 20 18  Core R&D: 24% of Total Revenue + Accelerated recruitment in ongoing Phase III trials + Investments in transformative technologies such as cell therapy and radioconjugates + Positive data read-outs for high-value pipeline opportunities that have ungated late-stage trials + Addition of BD related R&D SG&A expense 4,864 (1) (2) 3,802 2 1  Core SG&A: 26% of Total Revenue Other operating income and expense6 79 30 33 71 19 23 Operating Profit 3,508 28 32 4,584 12 14 Operating Margin (%) 24 3pp 4pp 32 - 1pp Net finance expense 371 8 10 303 6 9 + Debt issued in 2024 at higher interest rates Tax rate (%) 22 2pp 2pp 21 2pp 2pp  Variations in the tax rate can be expected between periods EPS ($) 1.58 27 31 2.17 10 12 For monetary values the unit of change is percent; for Gross Margin, Operating Margin and Tax rate the unit of change is percentage points. In the expense commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a ‘+’ symbol beside an R&D expense comment indicates that the item resulted in an increase in the R&D expense relative to the prior year period. Corporate and business development CSPC In June 2025, AstraZeneca entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited to discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases. CSPC’s research will utilise its AI-driven, dual-engine efficient drug discovery platform. CSPC will receive an upfront payment of $110m, of which $60m has been capitalised as an Intangible asset, and is also eligible to receive up to $1.62bn in potential development milestone payments and up to $3.6bn in sales milestone payments, plus potential single- digit royalties based on annual net sales of the products. AstraZeneca will have rights to exercise options for exclusive licenses to develop and commercialise worldwide candidates identified under this agreement. EsoBiotec In May 2025, AstraZeneca completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, with potential use in oncology and immune-mediated diseases. AstraZeneca has acquired all outstanding equity of EsoBiotec for a total consideration of up to $1bn, on a cash and debt free basis. This includes an initial payment of $403m, and up to $575m in contingent consideration based on development and regulatory milestones. US investment plans In July 2025, AstraZeneca announced plans to invest $50bn in US manufacturing and R&D by 2030. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. ===== SIDA 5 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 5 Sustainability highlights AstraZeneca introduced an updated Sustainability strategy which focuses on the Company’s sustainability impact and how it does business. This strategy evolution recognises the connection between business growth and the need to address the major health challenges of our time, and aims to support the health of people, society and the planet. Reporting calendar The Company intends to publish its 9M and Q3 2025 results on 6 November 2025. Conference call A conference call and webcast for investors and analysts will begin today, 29 July 2025, at 14:00 UK time. Details can be accessed via astrazeneca.com. Reporting changes since FY 2024 Product Revenue Effective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal ‘Product Revenue’ representing the summation of Product Sales and Alliance Revenue. Product Revenue and Collaboration Revenue form Total Revenue. Product Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue. Full descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group's Annual Report and Form 20-F Information 2024. Gross Margin Effective 1 January 2025, the Group has replaced the measure of ‘Product Sales Gross Margin’ with the measure of ‘Gross Margin’. Previously, the measure excluded margin related to Alliance Revenue and Collaboration Revenue. The new measure is calculated using Gross profit as a percentage of Total Revenue, thereby encompassing all revenue categories, and is intended to provide a more comprehensive measure of total performance. Notes 1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2025 vs. 2024. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results. 2. Effective 1 January 2025, the Group has updated its presentation of Total Revenue, adding a new subtotal of Product Revenue, the sum of Product Sales and Alliance revenue. For further details, see Note 1: ‘Basis of preparation and accounting policy’ in the Notes to the Interim Financial Statements. 3. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Table 9 in the Financial Performance section of this document. 4. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement. 5. Effective 1 January 2025, the Group has updated its presentation of Gross Margin. For further details, see Note 1: ‘Basis of preparation and accounting policy’ in the Notes to the Interim Financial Statements 6. Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group’s financial statements. ===== SIDA 6 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 6 Table 3: Product Revenue by medicine H1 2025 % Change Q2 2025 % Change $m % Total Actual CER $m % Total Actual CER Tagrisso 3,488 12 9 10 1,810 13 13 12 Imfinzi 2,716 10 20 21 1,455 10 27 26 Calquence 1,634 6 8 9 872 6 10 10 Lynparza 1,564 6 8 9 838 6 13 11 Enhertu 1,262 5 35 38 666 5 41 42 Zoladex 587 2 4 6 294 2 4 5 Truqap 302 1 >2x >2x 170 1 84 84 Imjudo 170 1 25 25 89 1 20 18 Datroway 14 - n/m n/m 11 - n/m n/m Other Oncology 217 1 (10) (8) 107 1 (12) (13) Oncology Product Revenue 11,954 43 15 16 6,312 44 18 18 Farxiga 4,209 15 11 13 2,151 15 11 10 Crestor 636 2 8 10 320 2 9 9 Brilinta 520 2 (22) (21) 215 1 (37) (38) Lokelma 328 1 31 32 175 1 29 27 Seloken 309 1 (2) 2 148 1 (2) 1 roxadustat 152 1 (9) (8) 73 1 (18) (18) Wainua 84 - >4x >4x 44 - >2x >2x Other CVRM 274 1 (27) (26) 138 1 (27) (28) CVRM Product Revenue 6,512 23 6 7 3,264 23 3 3 Symbicort 1,438 5 (4) (2) 715 5 (1) (1) Fasenra 920 3 18 18 502 3 19 18 Breztri 583 2 28 29 283 2 21 20 Tezspire 483 2 73 73 267 2 66 65 Pulmicort 264 1 (30) (28) 106 1 (32) (32) Saphnelo 304 1 49 49 167 1 49 48 Airsupra 70 - >3x >3x 42 - >2x >2x Other R&I 172 1 (5) (5) 68 - (19) (20) R&I Product Revenue 4,234 15 12 13 2,150 15 13 12 Beyfortus 238 1 >2x >2x 126 1 >3x >3x Synagis 162 1 (36) (33) 49 - (39) (37) FluMist 10 - 20 16 10 - >5x >5x Other V&I 1 - (91) (91) - - (78) (78) V&I Product Revenue 411 1 17 18 185 1 56 54 Ultomiris 2,228 8 23 24 1,177 8 25 23 Soliris 974 3 (32) (30) 530 4 (24) (22) Strensiq 746 3 14 15 395 3 16 15 Koselugo 275 1 11 13 137 1 20 18 Other Rare Disease 113 - 12 14 55 - 16 14 Rare Disease Product Revenue 4,336 16 2 3 2,294 16 7 7 Nexium 434 2 (8) (5) 201 1 (11) (11) Others 82 - (20) (20) 43 - (12) (13) Other Medicines Product Revenue 516 2 (10) (8) 244 2 (11) (11) Product Revenue 27,963 100 9 11 14,449 100 12 11 Alliance Revenue included above: Enhertu 834 3 22 24 436 3 27 27 Tezspire 285 1 58 58 155 1 50 50 Beyfortus 109 - >4x >3x 27 - >4x >3x Datroway 14 - n/m n/m 10 - n/m n/m Other Alliance Revenue 51 - 4 2 26 - (11) (11) Alliance Revenue 1,293 5 38 38 654 5 36 35 Revenue drivers ===== SIDA 7 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 7 Table 4: Collaboration Revenue H1 2025 % Change Q2 2025 % Change $m Actual CER $m Actual CER Farxiga: sales milestones 77 57 56 3 (36) (38) Others 5 n/m n/m 5 n/m n/m Collaboration Revenue 82 68 66 8 >2x >2x Table 5: Total Revenue by Therapy Area H1 2025 % Change Q2 2025 % Change $m % Total Actual CER $m % Total Actual CER Oncology 11,955 43 15 16 6,312 44 18 18 CVRM 6,588 23 6 8 3,266 23 3 3 R&I 4,234 15 12 13 2,150 15 13 12 V&I 411 1 17 18 185 1 56 54 BioPharmaceuticals 11,232 40 8 10 5,601 39 8 7 Rare Disease 4,336 15 2 3 2,294 16 7 7 Other Medicines 522 2 (9) (7) 250 2 (9) (9) Total Revenue 28,045 100 9 11 14,457 100 12 11 Table 6: Total Revenue by region H1 2025 % Change Q2 2025 % Change $m % Total Actual CER $m % Total Actual CER US 11,970 43 12 12 6,323 44 13 14 Emerging Markets ex. China 4,182 15 12 19 2,043 14 16 21 China 3,515 13 4 5 1,710 12 5 5 Emerging Markets 7,697 27 8 12 3,754 26 11 13 Europe 5,825 21 9 8 3,066 21 12 8 Established ROW 2,554 9 5 5 1,315 9 5 2 Total Revenue 28,045 100 9 11 14,457 100 12 11 Total Revenue by Medicine Oncology Tagrisso H1 2025 $m Total Revenue % Change Actual CER  Strong demand growth across all indications and key regions, leading combination in 1L NSCLC (FLAURA2) US 1,439 12 12  Underlying demand growth more than offset Medicare Part D redesign Emerging Markets 1,008 10 13 Europe 658 5 5  Demand growth partially offset by pricing pressure in certain major markets Established RoW 383 3 3  Demand growth offset by seasonal variability in Japan in Q1 2025 Total 3,488 9 10 Imfinzi H1 2025 $m Total Revenue % Change Actual CER  Strong growth from new launch indications in bladder cancer (NIAGARA) and lung cancer (ADRIATIC, AEGEAN) US 1,572 31 31  Demand growth from new launches, further growth in ES-SCLC (CASPIAN) Emerging Markets 294 20 28  Increased demand in GI and new launches in lung cancer Europe 537 17 17  Growth from GI indications and early momentum from lung cancer launches Established RoW 313 (11) (11)  Mandatory price reductions in Japan in Feb 2024 (25%), and Aug 2024 (11%), increased competition in BTC Total 2,716 20 21 ===== SIDA 8 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 8 Calquence H1 2025 $m Total Revenue % Change Actual CER  Growth from sustained BTKi leadership in front-line CLL (ELEVATE-TN) US 1,090 4 4  Demand growth driven by increased share of new starts in CLL, 1L MCL (ECHO) launch and improved affordability offsetting Medicare Part D redesign and discounts to secure preferential formulary placement Emerging Markets 103 36 49 Europe 368 15 15 Established RoW 73 12 15 Total 1,634 8 9 Lynparza H1 2025 $m Total Revenue % Change Actual CER  Sustained global PARP inhibitor market leadership across four tumour types (ovarian, breast, prostate, pancreatic) US 689 14 14  Share gains across breast and prostate indications Emerging Markets 323 1 4  Affected by generic launches in China in Q4 2024 Europe 425 7 6  Launches in breast and prostate cancers (OlympiA and PROpel) Established RoW 127 1 2  Gains in 1L ovarian cancer offset by lower testing rate in prostate cancer Total 1,564 8 9 Enhertu Combined sales of Enhertu, recorded by Daiichi Sankyo and AstraZeneca, amounted to $2,289m in H1 2025 (H1 2024: $1,772m). US in- market sales, recorded by Daiichi Sankyo, amounted to $1,128m in H1 2025 (H1 2024: $865m). AstraZeneca's European revenue includes a mid single-digit percentage royalty on Daiichi Sankyo's sales in Japan, recorded as Alliance Revenue. H1 2025 $m Total Revenue % Change Actual CER  Standard of care in HER2-positive (DESTINY-Breast03) and HER2-low (DESTINY- Breast04) metastatic breast cancer, early uptake in other cancers  US 543 31 31  Accelerating uptake in chemotherapy naïve HER2-low and -ultralow breast cancer (DESTINY-Breast06) Emerging Markets 365 63 72  Rapid adoption post-NRDL enlistment of HER2-positive and HER2-low breast cancer from 1 January 2025 Europe 312 19 19  Early launch uptake in chemotherapy naïve HER2-low breast cancer Established RoW 42 35 41 Total 1,262 35 38 Other Oncology medicines H1 2025 $m Total Revenue % Change Actual CER Zoladex 588 4 6  Growth across Emerging Markets Truqap 302 >2x >2x  Demand growth in second-line biomarker-altered population Imjudo 170 25 25  Continued growth driven by lung (POSEIDON) and HCC (HIMALAYA) Datroway 14 n/m n/m  Uptake from breast cancer following launch in the US Other Oncology 217 (10) (8)  Faslodex generic erosion across markets Other Oncology includes $16m of Total Revenue from Orpathys, partnered with HUTCHMED. BioPharmaceuticals - CVRM Farxiga H1 2025 $m Total Revenue % Change Actual CER  Growth driven by HF and CKD indications, SGLT2 class growth supported by cardiorenal guidelines US 803 (8) (8)  Q1 2024 benefitted from launch of authorised generic Emerging Markets 1,730 17 23  Continued strong growth despite generic competition in some markets Europe 1,448 17 17  Continued strong class growth and market share gains Established RoW 304 17 17  Sales milestone of $74m from partner in Japan in Q1 2025 Total 4,285 12 14 ===== SIDA 9 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 9 Other CVRM medicines H1 2025 $m Total Revenue % Change Actual CER Crestor 636 8 10  Continued sales growth driven by Emerging Markets Brilinta 520 (22) (21)  Decline driven by generic entry in the US and Europe in Q2 2025 Seloken 309 (2) 2  Majority of revenue driven by Emerging Markets Lokelma 328 31 32  Strong growth in all major regions roxadustat 152 (9) (8)  Decline driven by generic competition Wainua 84 >4x >4x  Majority of revenue from US, first launches in ex-US markets in Q2 2025 Other CVRM 274 (27) (26) BioPharmaceuticals - R&I Symbicort H1 2025 $m Total Revenue % Change Actual CER  Global market leader in a stable ICS/LABA class, treating COPD and asthma US 598 - -  Resilient demand for authorised generic Emerging Markets 400 (11) (8)  China affected by ICS/LABA class erosion in COPD in favour of triple therapy Europe 272 (5) (5)  Continued generic erosion Established RoW 168 7 10 Total 1,438 (4) (2) Fasenra H1 2025 $m Total Revenue % Change Actual CER  Expanded severe eosinophilic asthma market share leadership in IL-5 class, further fuelled by first wave market launches for EGPA indication US 556 16 16  Sustained double-digit volume growth with expanded class leadership Emerging Markets 52 26 32  Asthma launch momentum across key markets  Europe 229 19 19  Sustained leadership in severe eosinophilic asthma Established RoW 83 19 20  Strong growth supported by recent EGPA launch in Japan Total 920 18 18 Breztri H1 2025 $m Total Revenue % Change Actual CER  Fastest growing medicine within the expanding FDC triple class (ICS/LABA/LAMA), treating COPD US 295 31 31  Consistent share growth within expanding FDC triple class Emerging Markets 156 19 21  Growth from market share leadership in China with strong FDC triple class penetration. Unfavourable inventory movement in the second quarter Europe 87 34 34  Sustained growth from market share gain and new launches Established RoW 45 34 36  Increasing market share in Japan Total 583 28 29 Tezspire Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $826m in H1 2025 (H1 2024: $507m). H1 2025 $m Total Revenue % Change Actual CER  Sustained demand growth in severe asthma with launch momentum across multiple markets US 285 58 58  Continued strong demand growth with majority of patients new to biologics Emerging Markets 16 >3x >3x  Strong continued launch uptake Europe 128 >2x >2x  Maintained new-to-brand leadership across multiple markets and new launches Established RoW 54 61 63  Strong growth driven by Japan Total 483 73 73 Other R&I medicines H1 2025 $m Total Revenue % Change Actual CER Pulmicort 264 (30) (28)  Generic competition in Emerging Markets (~80% of revenue) Saphnelo 304 49 49  Strong US demand growth, ongoing launches in Europe and Established RoW Airsupra 70 >3x >3x  Strong US launch momentum and volume uptake Other R&I 172 (5) (5) ===== SIDA 10 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 10 Biopharmaceuticals - V&I Beyfortus Total Revenue reflects the sum of Product Sales from AstraZeneca’s sales of manufactured Beyfortus product to Sanofi and Alliance Revenue from AstraZeneca’s share of gross profits and royalties on sales of Beyfortus in major markets outside the US. H1 2025 $m Total Revenue % Change Actual CER Beyfortus 238 >2x >2x  Increased capacity and strong demand Synagis 162 (36) (33)  Competition from Beyfortus FluMist 10 20 16 Other V&I 1 (91) (91) Rare Disease Ultomiris Ultomiris Total Revenue includes sales of Voydeya, which is approved as an add on treatment to Ultomiris and Soliris for the ~20-30% of PNH patients who experience clinically significant EVH. H1 2025 $m Total Revenue % Change Actual CER  Growth due to patient demand, both naïve to branded medicines and conversion from Soliris in all indications (gMG, NMOSD, aHUS and PNH) US 1,272 23 23  Demand growth across indications, including within the competitive gMG and PNH landscapes, minimal impact from Medicare Part D redesign Emerging Markets 113 71 82  Expansion into new markets and growth in patient demand Europe 498 21 21  Strong demand growth following recent launches; competition in gMG Established RoW 345 17 17  Continued conversion and strong demand following new launches Total 2,228 23 24 Soliris H1 2025 $m Total Revenue % Change Actual CER  Decline driven by conversion of patients to Ultomiris in all indications (gMG, NMOSD, aHUS, PNH), competition, and biosimilar pressure in Europe US 568 (30) (30)  Competition in gMG and PNH Emerging Markets 224 (12) (1)  Benefitted from favourable order timing in tender markets Europe 112 (57) (57)  Biosimilar competition in PNH and aHUS Established RoW 70 (40) (38) • Driven by conversion to Ultomiris Total 974 (32) (30) Strensiq H1 2025 $m Total Revenue % Change Actual CER  Growth driven by continued patient demand and geographic expansion US 584 10 10 • Demand growth, offset by Medicare Part D redesign Emerging Markets 50 61 67 Europe 57 19 20 Established RoW 55 24 23 Total 746 14 15 Other Rare Disease medicines H1 2025 $m Total Revenue % Change Actual CER Koselugo 275 11 13  Growth driven by continued patient demand and geographic expansion Other Rare Disease 113 12 14  Other Rare Disease medicines include Kanuma and Beyonttra (JP only) Other Medicines H1 2025 $m Total Revenue % Change Actual CER Nexium 434 (8) (5)  Growth in Emerging Markets, generic erosion elsewhere Others 88 (15) (15)  Generic erosion ===== SIDA 11 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 11 This section covers R&D events and milestones that occurred between 29 April 2025 and 28 July 2025. A comprehensive view of AstraZeneca's pipeline of medicines in human trials can be found in the latest Clinical Trials Appendix, available on AstraZeneca’s investor relations webpage. The Clinical Trials Appendix includes tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the pipeline. Oncology AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical congresses since the prior results announcement: the American Society of Clinical Oncology Annual Meeting 2025 and the European Hematology Association Congress 2025. Across the two meetings, more than 100 abstracts were presented featuring 23 approved and potential new medicines including 25 oral presentations. Calquence Approval EU ECHO May 2025  In combination with bendamustine and rituximab for the treatment of previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant. Approval EU ACE-LY-004 May 2025 New disclosure  For the treatment of relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor. Approval EU AMPLIFY June 2025  Fixed-duration regimen of Calquence in combination with venetoclax, with or without obinutuzumab, for the treatment of previously untreated chronic lymphocytic leukaemia. Datroway Approval US TROPION-Lung05, Tropion-Lung01 June 2025  For the treatment of locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. Enhertu Phase III readout DESTINY-Breast11 May 2025  Positive high-level results demonstrated that Enhertu followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pCR rate versus standard-of-care (dose-dense doxorubicin and cyclophosphamide followed by THP) when used in the neoadjuvant setting in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Data presentation ASCO DESTINY-Breast09 June 2025  Positive results from the DESTINY-Breast09 Phase III trial in 1st-line HER2-positive metastatic breast cancer showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP (HR 0.56; 95% CI 0.44-0.71; p<0.00001). Median PFS was 40.7 months with Enhertu plus pertuzumab compared to 26.9 months for THP, as assessed by blinded independent central review. Imfinzi Phase III readout POTOMAC May 2025  Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with Imfinzi plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone. Approval China ADRIATIC May 2025 New disclosure  For the treatment of limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy. R&D progress ===== SIDA 12 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 12 Data presentation ASCO MATTERHORN June 2025  Positive results from the MATTERHORN Phase III trial in resectable early-stage gastric and gastroesophageal junction cancers showed perioperative treatment with Imfinzi in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone (EFS HR 0.71; 95% CI 0.58-0.86; p<0.001) versus chemotherapy alone. Estimated median EFS was not yet reached for the Imfinzi arm versus 32.8 months for the comparator arm. Approval Europe NIAGARA July 2025  For the treatment of resectable muscle-invasive bladder cancer in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder). Priority Review US MATTERHORN July 2025  For the treatment of resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction cancers. Tagrisso Approval Japan LAURA May 2025 New disclosure  As maintenance therapy after definitive chemoradiation therapy in locally advanced and unresectable EGFRm NSCLC. Phase III readout FLAURA2 July 2025  Positive high-level results from the final OS analysis of the FLAURA2 Phase III trial showed Tagrisso with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy for patients with 1st-line locally advanced or metastatic EGFRm NSCLC. Orpathys Approval China SACHI June 2025 New disclosure  In combination with Tagrisso for the treatment of patients with locally advanced or metastatic non-squamous EGFRm NSCLC with MET amplification who have progressed following EGFR tyrosine kinase inhibitor therapy. camizestrant Data presentation ASCO SERENA-6 June 2025  Positive results from the SERENA-6 Phase III trial showed that camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) reduced the risk of disease progression or death by 56% compared to standard-of-care treatment (HR 0.44; 95% CI 0.31-0.60; p<0.00001) as assessed by investigator compared to continuing standard-of-care treatment with an aromatase inhibitor in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with HR- positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation. Median PFS was 16.0 months for patients who switched to the camizestrant combination versus 9.2 months for the comparator arm. BioPharmaceuticals – CVRM baxdrostat Phase III readout BaxHTN July 2025  Positive high-level results from the BaxHTN Phase III trial in uncontrolled or treatment resistant hypertension showed that two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients received baxdrostat or placebo on top of standard-of- care. ===== SIDA 13 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 13 BioPharmaceuticals – R&I Breztri Phase III readout KALOS/LOGOS May 2025  Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that Breztri met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with inhaled ICS/LABA medicines. CHMP opinion EU NGP programme July 2025  Trixeo (Breztri), already licensed for the treatment of chronic obstructive pulmonary disease (COPD) in adults, has received a positive opinion from the CHMP endorsing it for use with an innovative, next-generation propellant with near-zero global warming potential. Based on the CHMP positive opinion, AstraZeneca will now begin to transition its Trixeo supply to the next-generation propellant in Europe Fasenra Phase III readout NATRON June 2025 New disclosure  Positive high-level results from the NATRON Phase III trial showed treatment with Fasenra, dosed monthly in a single injection, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of time to first worsening or flare versus placebo in patients with hypereosinophilic syndrome. The safety and tolerability profile for Fasenra in this trial was consistent with the known profile of the medicine. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities. Saphnelo Phase III readout AZALEA July 2025 New disclosure  Positive high-level results demonstrated that Saphnelo resulted in statistically significant and clinically meaningful improvement in the primary endpoint, BICLA Response at week 52, compared to placebo, in Asian patients with moderate to severe SLE despite standard-of-care. Improvements across secondary endpoints were also observed. The safety profile was generally consistent with the established safety profile. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities. Airsupra Data presentation ATS 2025 BATURA May 2025  Positive full results from the BATURA Phase IIIb trial of Airsupra demonstrated a 47% reduction (5.1%, 9.1%, hazard ratio 0.53; 95% CI, 0.39-0.73; p<0.001) in the risk of severe exacerbations in mild asthma compared with albuterol alone. In a key secondary endpoint, adults and adolescents ages 12 and older receiving Airsupra had 63% lower exposure to total systemic corticosteroids (SCS) (p<0.001) over the treatment period compared with albuterol-alone. Similar reductions in all primary and secondary endpoints were seen in a prespecified subgroup of adult patients (≥18 years) on treatment. BioPharmaceuticals – V&I IVX-A12 Programme update NCT06481579 April 2025  The Phase II trial to characterise safety and immunogenicity in adults 60 years of age and older has completed, and IVX-A12 was shown to be well-tolerated and immunogenic. AstraZeneca has identified opportunities to further enhance the vaccine and is now progressing the improved RSV/hMPV combination. ===== SIDA 14 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 14 Rare Disease Alexion, AstraZeneca Rare Disease, presented new data at the European Hematology Association Congress 2025, since prior earnings. Nine abstracts were presented in rare haematology, in both PNH and HSCT-TMA. gefurulimab Phase III readout PREVAIL July 2025  Positive high-level results from a global, randomised, double-blind, placebo- controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody- positive (Ab+) generalised myasthenia gravis (gMG) showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo. anselamimab Phase III readout CARES Programme July 2025  High-level results from the CARES (301/2) Phase III clinical programme showed that anselamimab did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain amyloidosis. The primary endpoint was defined as a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalisations (CVH). Anselamimab showed highly clinically meaningful improvement in time to ACM and frequency of CVH in a prespecified subgroup of patients, compared to placebo. Ultomiris Data presentation EHA ALXN1210-TMA-314 June 2025  Initial results from the ALXN1210-TMA-314 Phase III, single arm trial evaluating Ultomiris in paediatric patients with HSCT-TMA. Ultomiris demonstrated clinically meaningful improvements in the individual components of TMA response (platelets, LDH and urinary protein/creatinine ratio) at 26 weeks, and a clinically meaningful improvement in the secondary endpoint of overall survival at six months. 58.5% (95% CI: 42.1-73.7) and 53.7% (95% CI: 37.4-69.3) of participants met the predefined response criteria for platelet and urine protein/creatinine ratio, respectively, and 36.6% (95% CI: 22.1-53.1) of participants normalised LDH from baseline during the 26-week treatment period. Overall survival was 92.6% (95% CI: 78.8-97.6) at day 100 and 87.2% (95% CI: 71.8-94.5) at week 26. ===== SIDA 15 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 15 Sustainability highlights AstraZeneca introduced an updated Sustainability strategy which focuses on the Company’s sustainability impact and how it does business. This strategy evolution recognises the connection between business growth and the need to address the major health challenges of our time, and aims to support the health of people, society and the planet. The Company will continue to drive sustainable impact through action on climate and nature, health equity and health systems resilience, leveraging the latest science and innovation. It will also focus on creating long-term value, resilience and trust by operating responsibly and ethically, maintaining robust governance, investing in its people and following its Values – In May 2025, the Company published its second Sustainability Impact publication which introduces the updated strategy and shares examples of impact from across the business. It also presented 2024 Sustainability Highlights to investors and analysts – AstraZeneca was named in the top 20 of TIME’s Most Sustainable Companies, its highest ranking to date in the list of 500 businesses. AstraZeneca and Alexion were also included in Newsweek’s World’s Greenest Companies 2025 – AstraZeneca achieved the top ranking in IDEA Pharma’s index for 2025, coming first for “Invention” and joint third for “Innovation”. This annual ranking assesses companies' ability to develop and commercialise products. – AstraZeneca has been A-rated for Supplier Engagement by CDP for 2024 and is on the Leaderboard for the third consecutive year, recognising its extensive supply chain engagement and focus on disclosing carbon emissions data and actions to CDP – The Company also ranked fourth in the 2025 Gartner Top 25 Supply Chains, the highest ranking for a pharmaceutical company this year – AstraZeneca SVP, Chief Digital Officer and CIO Cindy Hoots was ranked in the top 20 of this year's Top 100 Women in Technology recognising her leadership in driving a digital-first strategy Sustainability impact Climate and nature – Reducing the carbon impact of pressurised metered dose inhalers is a key product-related element of AstraZeneca’s Ambition Zero Carbon strategy. With an innovative next- generation propellant with 99.9% lower Global Warming Potential than current propellants, Breztri/Trixeo Aerosphere has received positive CHMP opinion and AstraZeneca will now begin to transition its Trixeo supply to the next- generation propellant in Europe – At London Climate Action Week, AstraZeneca joined His Majesty King Charles III, ministers from the UK and Brazil, and global leaders for an event on ‘Nature Action: Mobilising Frameworks and Finance’ and was also represented at several panel and roundtable discussions. The Company celebrated the use of 100% renewable energy for both heat and power at its Macclesfield site – The company participated in engagements with French, Italian and UK stakeholders, including a Circular Bioeconomy Alliance event in Rome in the presence of His Majesty King Charles III, as well as an event hosted by the French government on health systems decarbonisation. AstraZeneca showcased its pioneering work in quantifying the environmental impact of patient care, including its new Care pathways Environmental Sustainability Assessment tool (CARESA) – EVP International, Iskra Reic met with China’s Vice President Han Zheng to discuss the green transition as part of the Sustainable Markets Initiative (SMI) China Forum in Beijing. She underscored AstraZeneca’s commitment to Healthy China 2030 and Common Health, as well as the Company’s collaborative efforts to decarbonise the health sector in Chinese media interviews Health equity – AstraZeneca’s Qure.ai partnership reached a significant milestone, achieving five million chest X-rays assessed by AI for lung cancer in more than 20 countries. This partnership has resulted in nearly 50,000 referrals for follow-up testing to date and demonstrates the transformative potential of technology and advanced data analytics for early lung cancer detection – At the World Health Assembly (WHA) in Geneva, Switzerland, AstraZeneca organised the first cancer planners’ summit with the Union for International Cancer Control, attended by more than 100 delegates from over 50 countries, and also hosted events on lung health, kidney disease and rare diseases. The Company engaged with leaders from countries including the US, Brazil, the UAE, Egypt, Malaysia and Spain as well as NGOs on topics spanning health equity, resilience and climate action – Through the Company’s flagship health equity initiative, Healthy Heart Africa, the Company engaged at Africa Health ExCon 2025, where a national strategy for managing chronic kidney disease in Egypt was launched with government representatives Health systems resilience – The Partnership for Health System Sustainability and Resilience (PHSSR) which the Company co-founded in 2020, added to its growing body of evidence, launching its EU Expert Advisory Group's report on sustainable healthcare financing in Europe – AstraZeneca convened the PHSSR Summit 2025 at EXPO in Osaka, Japan with AstraZeneca Chair Michel Demaré, Japanese government and health systems stakeholders. The Summit focused on action on non- communicable diseases (NCDs) and healthcare digitisation. Additional high- level engagements at EXPO 2025 this quarter included an event on transforming the delivery of healthcare with a focus on COPD, attended by EVP BioPharmaceuticals Business, Ruud Dobber, and engagements on rare disease led by Marc Dunoyer, CEO Alexion – At Abu Dhabi Global Health Week, a Company delegation led by Chair Michel Demaré and EVP International, Iskra Reic, focused on sustainable health system investment and health equity Sustainability ===== SIDA 16 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 16 Reporting currency All narrative on growth and results in this section is based on actual exchange rates, and financial figures are in US$ millions ($m), unless stated otherwise. Reporting period The performance shown in this announcement covers the six-month period to 30 June 2025 ('H1 2025') compared to the six-month period to 30 June 2024 (‘H1 2024’), and the three- month period to 30 June 2025 ('the quarter' or 'Q2 2025') compared to the three-month period to 30 June 2024 (‘Q2 2024’), unless stated otherwise. Core financial measures Core financial measures, EBITDA, Net debt, Gross Margin, Operating Margin and CER are non-GAAP financial measures because they cannot be derived directly from the Group's Condensed consolidated interim financial statements. Management believes that these non- GAAP financial measures, when provided in combination with Reported results, provide investors and analysts with helpful supplementary information to understand better the financial performance and position of the Group on a comparable basis from period to period. These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP. Core financial measures (cont.) Core financial measures are adjusted to exclude certain significant items: – Charges and provisions related to our global restructuring programmes, which includes charges that relate to the impact of restructuring programmes on our capitalised manufacturing assets and IT assets – Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges relating to IT assets – Other specified items, principally comprising acquisition-related costs and credits, which include the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain Other payables arising from intangible asset acquisitions, remeasurement adjustments relating to certain Other payables and debt items assumed from the Alexion acquisition and legal settlements – The tax effects of the adjustments above are excluded from the Core Tax charge Details on the nature of Core financial measures are provided on page 70 of the Annual Report and Form 20-F Information 2024. Reference should be made to the Reconciliation of Reported to Core financial measures table included in the Financial Performance section in this announcement. Definitions Gross Margin is defined as Gross Profit as a percentage of Total Revenue. EBITDA is defined as Reported Profit before tax after adding back Net finance expense, results from Joint ventures and associates and charges for Depreciation, amortisation and impairment. Reference should be made to the Reconciliation of Reported Profit before tax to EBITDA included in the Financial Performance section in this announcement. Operating margin is defined as Operating profit as a percentage of Total Revenue. Net debt is defined as Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash equivalents, Other investments, and Net derivative financial instruments. Reference should be made to Note 3 'Net debt', included in the Notes to the interim financial statements in this announcement. The Company strongly encourages investors and analysts not to rely on any single financial measure, but to review AstraZeneca's financial statements, including the Notes thereto, and other available Company reports, carefully and in their entirety. Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree to totals. Operating and financial review ===== SIDA 17 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 17 Table 7: Reported Profit and Loss H1 2025 H1 2024 % Change Q2 2025 Q2 2024 % Change $m $m Actual CER $m $m Actual CER - Product Sales 26,670 24,629 8 10 13,795 12,452 11 10 - Alliance Revenue 1,293 939 38 38 654 482 36 35 Product Revenue 27,963 25,568 9 11 14,449 12,934 12 11 Collaboration Revenue 82 49 68 66 8 4 >2x >2x Total Revenue 28,045 25,617 9 11 14,457 12,938 12 11 Cost of sales (4,714) (4,401) 7 10 (2,473) (2,183) 13 9 Gross profit 23,331 21,216 10 11 11,984 10,755 11 12 Distribution expense (278) (267) 4 6 (143) (132) 8 8 R&D expense (6,707) (5,791) 16 16 (3,548) (3,008) 18 16 SG&A expense (9,356) (9,424) (1) - (4,864) (4,929) (1) (2) Other operating income & expense 192 127 52 53 79 60 30 33 Operating profit 7,182 5,861 23 24 3,508 2,746 28 32 Net finance expense (636) (645) (1) - (371) (343) 8 10 Joint ventures and associates (17) (19) (7) (9) (10) (6) >2x 91 Profit before tax 6,529 5,197 26 27 3,127 2,397 30 34 Taxation (1,160) (1,089) 7 7 (679) (469) 45 49 Tax rate 18% 21% 22% 20% Profit after tax 5,369 4,108 31 32 2,448 1,928 27 31 Earnings per share $3.46 $2.65 31 32 $1.58 $1.24 27 31 Table 8: Reconciliation of Reported Profit before tax to EBITDA H1 2025 H1 2024 % Change Q2 2025 Q2 2024 % Change $m $m Actual CER $m $m Actual CER Reported Profit before tax 6,529 5,197 26 27 3,127 2,397 30 34 Net finance expense 636 645 (1) - 371 343 8 10 Joint ventures and associates 17 19 (7) (9) 10 6 >2x 91 Depreciation, amortisation and impairment 2,673 2,534 5 5 1,389 1,279 9 7 EBITDA 9,855 8,395 17 18 4,897 4,025 22 24 Table 9: Reconciliation of Reported to Core financial measures: H1 2025 For the half year ended 30 June Reported Restructuring Intangible Asset Amortisation & Impairments Other Core % Change $m $m $m $m $m Actual CER Gross profit 23,331 (70) 17 1 23,279 9 10 - Gross Margin 83% 83% - - Distribution expense (278) - - - (278) 4 6 R&D expense (6,707) 101 62 3 (6,541) 17 17 - R&D % of Total Revenue 24% 23% -2pp -1pp SG&A expense (9,356) 76 1,943 78 (7,259) 2 3 - SG&A % of Total Revenue 33% 26% +2pp +2pp Total operating expense (16,341) 177 2,005 81 (14,078) 8 9 Other operating income & expense 192 (6) - - 186 50 51 Operating profit 7,182 101 2,022 82 9,387 12 13 - Operating Margin 26% 33% +1pp +1pp Net finance expense (636) - - 118 (518) (3) (1) Taxation (1,160) (30) (386) (49) (1,625) 1 2 EPS $3.46 $0.05 $1.06 $0.09 $4.66 16 17 Financial performance ===== SIDA 18 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 18 Table 10: Reconciliation of Reported to Core financial measures: Q2 2025 For the quarter ended 30 June Reported Restructuring Intangible Asset Amortisation & Impairments Other Core % Change $m $m $m $m $m Actual CER Gross profit 11,984 (78) 9 (1) 11,914 11 11 - Gross Margin 83% 82% -1pp - Distribution expense (143) (3) - - (146) 10 10 R&D expense (3,548) 41 52 2 (3,453) 20 18 - R&D % of Total Revenue 25% 24% -2pp -1pp SG&A expense (4,864) 26 986 50 (3,802) 2 1 - SG&A % of Total Revenue 34% 26% +3pp +3pp Total operating expense (8,555) 64 1,038 52 (7,401) 10 9 Other operating income & expense 79 (7) - (1) 71 19 23 Operating profit 3,508 (21) 1,047 50 4,584 12 14 - Operating Margin 24% 32% - 1pp Net finance expense (371) - - 68 (303) 6 9 Taxation (679) (2) (199) (31) (911) 23 26 EPS $1.58 $(0.01) $0.55 $0.05 $2.17 10 12 Profit and Loss drivers Gross profit The stable Gross Margin (Reported and Core) in H1 2025 was a result of: – Positive effects from geographic mix – Negative effects from product mix. The rising contribution of Product Sales with profit sharing arrangements (Lynparza, Enhertu, Tezspire, Koselugo) has a negative impact on Gross Margin because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners. The profit share paid to partners is recorded in AstraZeneca’s Cost of sales line – Pricing adjustments, for example to sales reimbursed by the Medicare Part D programme in the US, diluted the Gross Margin. Variations in Gross Margin performance between periods can continue to be expected due to product seasonality, foreign exchange fluctuations, and other effects. R&D expense The change in R&D expense (Reported and Core) in the period was impacted by: – Positive data read-outs for high-value pipeline opportunities that have ungated late-stage trials – Investment in platforms, new technology and capabilities to enhance R&D capabilities – Addition of R&D projects following completion of previously announced business development activity SG&A expense – The change in SG&A expense (Reported and Core) in the period was driven primarily by market development activities for launches and to support continued growth in existing brands Other operating income and expense – Other operating income in H1 2025 consisted primarily of royalties and an upfront fee on a divestment Net finance expense Core Net finance expense decreased 3% (1% at CER) in H1 2025, mainly driven by an adjustment of interest on tax, due to a reduction of tax liabilities relating to prior periods, recognised in the first quarter. Core Net finance expense increased 6% (9% at CER) in Q2 2025, mainly driven by a reduction in short-term deposits. Taxation The effective Reported and Core tax rates for the six months to 30 June 2025 were 18% (H1 2024: 21% and 20% respectively). These tax rates benefited from a reduction of tax liabilities arising from updates to estimates of prior period tax liabilities following settlements with tax authorities in Q1 2025. The cash tax paid for the six months ended 30 June 2025 was $1,549m (H1 2024: $1,337m), representing 24% of Reported Profit before tax (H1 2024: 26%). Dividend The interim dividend declared with H1 2025 results increased by 3% to $1.03. ===== SIDA 19 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 19 Cash Flow Table 11: Cash Flow summary: H1 2025 For the half year ended 30 June 2025 $m 2024 $m Change $m Reported Operating profit 7,182 5,861 1,321 Depreciation, amortisation and impairment 2,673 2,534 139 Movement in working capital and short-term provisions (771) (584) (187) Gains on disposal of intangible assets (87) (21) (66) Fair value movements on contingent consideration arising from business combinations (30) 251 (281) Non-cash and other movements 304 (550) 854 Interest paid (623) (583) (40) Taxation paid (1,549) (1,337) (212) Net cash inflow from operating activities 7,099 5,571 1,528 Net cash inflow before financing activities 3,738 286 3,452 Net cash (outflow)/inflow from financing activities (2,189) 806 (2,995) Net cash flow The change in Net cash inflow from operating activities of $1,528m is primarily driven by the increased operating profit in 2025. The change in Net cash inflow before financing activities of $3,452m is primarily driven by the reduction in cash outflow relating to the Acquisitions of subsidiaries, net of cash acquired of $2,771m, which in 2024 related to the acquisition of Gracell Biotechnologies Inc. and the acquisition of Fusion Pharmaceuticals Inc. The change in Net cash (outflow)/inflow from financing activities of $2,995m is primarily driven by the issue of new long- term loans of $4,976m in 2024, with no issuance in 2025, and offset by the repayment of loans of $2,643m in 2024, with no repayment in 2025. Capital expenditure Capital expenditure on tangible assets and Software-related intangible assets amounted to $1,303m in H1 2025 (H1 2024: $903m). The increase of capital expenditure in 2025 was driven by investment in several major manufacturing projects and continued investment in technology upgrades. Net debt Net debt increased by $657m in the six months to 30 June 2025 to $25,227m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Details of the Company's solicited credit ratings and further details on Net debt are disclosed in Note 3. Net debt Table 12: Net debt summary At 30 Jun 2025 $m At 31 Dec 2024 $m At 30 Jun 2024 $m Cash and cash equivalents 7,058 5,488 6,916 Other investments 50 166 160 Cash and investments 7,108 5,654 7,076 Overdrafts and short-term borrowings (561) (330) (596) Commercial paper (1,470) - (2,453) Lease liabilities (1,633) (1,452) (1,241) Current instalments of loans (4,461) (2,007) (2,018) Non-current instalments of loans (24,714) (26,506) (27,225) Interest-bearing loans and borrowings (Gross debt) (32,839) (30,295) (33,533) Net derivatives 504 71 133 Net Debt (25,227) (24,570) (26,324) ===== SIDA 20 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 20 Summarised financial information for guarantee of securities of subsidiaries AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of 1.2% Notes due 2026, 4.8% Notes due 2027, 4.875% Notes due 2028, 1.75% Notes due 2028, 4.85% Notes due 2029, 4.9% Notes due 2030, 4.9% Notes due 2031, 2.25% Notes due 2031, 4.875% Notes due 2033 and 5% Notes due 2034 (the "AstraZeneca Finance USD Notes"). Each series of AstraZeneca Finance USD Notes has been fully and unconditionally guaranteed by AstraZeneca PLC. AstraZeneca Finance is 100% owned by AstraZeneca PLC and each of the guarantees issued by AstraZeneca PLC is full and unconditional and joint and several. The AstraZeneca Finance USD Notes are senior unsecured obligations of AstraZeneca Finance and rank equally with all of AstraZeneca Finance's existing and future senior unsecured and unsubordinated indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca Finance USD Notes is the senior unsecured obligation of AstraZeneca PLC and ranks equally with all of AstraZeneca PLC's existing and future senior unsecured and unsubordinated indebtedness. Each guarantee by AstraZeneca PLC is effectively subordinated to any secured indebtedness of AstraZeneca PLC to the extent of the value of the assets securing such indebtedness. The AstraZeneca Finance USD Notes are structurally subordinated to indebtedness and other liabilities of the subsidiaries of AstraZeneca PLC, none of which guarantee the AstraZeneca Finance USD Notes. AstraZeneca PLC manages substantially all of its operations through divisions, branches and/or investments in subsidiaries and affiliates. Accordingly, the ability of AstraZeneca PLC to service its debt and guarantee obligations is also dependent upon the earnings of its subsidiaries, affiliates, branches and divisions, whether by dividends, distributions, loans or otherwise. Please refer to the Consolidated financial statements of AstraZeneca PLC in our Annual Report on Form 20-F as filed with the SEC and information contained herein for further financial information regarding AstraZeneca PLC and its consolidated subsidiaries. For further details, terms and conditions of the AstraZeneca Finance USD Notes please refer to AstraZeneca PLC's reports on Form 6-K furnished to the SEC on 22 February 2024, 3 March 2023 and 28 May 2021. Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the Securities Act of 1933, as amended (the "Securities Act"), we present below the summary financial information for AstraZeneca PLC, as Guarantor, excluding its consolidated subsidiaries, and AstraZeneca Finance, as the issuer, excluding its consolidated subsidiaries. The following summary financial information of AstraZeneca PLC and AstraZeneca Finance is presented on a combined basis and transactions between the combining entities have been eliminated. Financial information for non- guarantor entities has been excluded. Intercompany balances and transactions between the obligor group and the non- obligor subsidiaries are presented on separate lines. Obligor group summarised statements Table 13: Obligor group summarised Statement of comprehensive income: H1 2025 For the half year ended 30 June 2025 $m 2024 $m Total Revenue - - Gross profit - - Operating loss - - Loss for the period (666) (545) Transactions with subsidiaries that are not issuers or guarantors 6,160 964 Table 14: Obligor group summarised Statement of financial position At 30 Jun 2025 $m At 30 Jun 2024 $m Current assets 43 13 Non-current assets 147 - Current liabilities (6,506) (4,795) Non-current liabilities (24,720) (27,133) Amounts due from subsidiaries that are not issuers or guarantors 23,554 20,730 Amounts due to subsidiaries that are not issuers or guarantors - - ===== SIDA 21 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 21 Capital allocation The Group’s capital allocation priorities include: investing in the business and pipeline; maintaining a strong, investment- grade credit rating; potential value- enhancing business development opportunities; and supporting the progressive dividend policy. In approving the declaration of dividends, the Board considers both the liquidity of the company and the level of reserves legally available for distribution. In FY 2025, the Company intends to increase the annual dividend per share declared to $3.20 per share. Dividends are paid to shareholders from AstraZeneca PLC, a Group holding company with no direct operations. The ability of AstraZeneca PLC to make shareholder distributions is dependent on the creation of profits for distribution and the receipt of funds from subsidiary companies. The consolidated Group reserves set out in the Condensed consolidated statement of financial position do not reflect the profit available for distribution to the shareholders of AstraZeneca PLC. In FY 2024, capital expenditure on tangible assets and Software-related intangible assets amounted to $2,218m. In FY 2025 the Group expects to increase expenditure on tangible assets and Software-related intangible assets by approximately 50%, driven by manufacturing expansion projects and investments in systems and technology. Foreign exchange The Company's transactional currency exposures on working capital balances, which typically extend for up to three months, are hedged where practicable using forward foreign exchange contracts against the individual companies' reporting currency. In addition, the Company's external dividend payments, paid principally in pound sterling and Swedish krona, are fully hedged from the time of their announcement to the payment date. Foreign exchange gains and losses on forward contracts transacted for transactional hedging are taken to profit or to Other comprehensive income if the contract is in a designated cashflow hedge. Table 15: Currency sensitivities Currency Primary Relevance Exchange rate vs USD (average rate in period) Annual impact of 5% weakening vs USD1 ($m) FY 20242 YTD 20253 Change (%) June 20254 Change (%) Total Revenue Core Operating Profit EUR Total Revenue 0.92 0.91 1 0.87 6 (461) (232) CNY Total Revenue 7.21 7.26 (1) 7.18 0 (313) (171) JPY Total Revenue 151.46 148.46 2 144.50 5 (179) (121) GBP Operating expense 0.78 0.77 2 0.74 6 (68) 124 SEK Operating expense 10.57 10.17 4 9.56 11 (9) 69 Other (557) (289) 1. Assumes the average exchange rate vs USD in FY 2025 is 5% lower than the average rate in FY 2024. The impact data are estimates, based on best prevailing assumptions around currency profiles. 2. Based on average daily spot rates 1 January 2024 to 31 December 2024. 3. Based on average daily spot rates 1 January 2025 to 30 June 2025. 4. Based on average daily spot rates 1 June 2025 to 30 June 2025. ===== SIDA 22 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 22 Related-party transactions There have been no significant related-party transactions in the period. Principal risks and uncertainties The Principal Risks and uncertainties facing the Group are set out on pages 65 to 66 of the Annual Report and Form 20-F Information 2024 and summarised below. They are not expected to change in respect of the second six months of the financial year and remain appropriate for the Group. In summary, the principal risks and uncertainties listed in the Annual Report and 20-F Information 2024 are: 1. Product pipeline risks: failure or delay in the delivery of our pipeline or launch of new medicines; failure to meet regulatory or ethical requirements for medicine development or approval 2. Commercialisation risks: pricing, affordability, access and competitive pressures; failures or delays in the quality or execution of the Group’s commercial strategies 3. Supply chain and business -execution risks: failure to maintain supply of compliant, quality medicines; failure in information technology or cybersecurity; failure to collect and manage data or AI in line with legal and regulatory requirements and strategic objectives 4. Legal, regulatory and compliance risks: safety and efficacy of marketed medicines is questioned; adverse outcome of litigation and / or governmental investigations; IP risks related to our products 5. Economic and financial risks: geopolitical and/or macroeconomic volatility disrupts the operation of our global business; failure to achieve strategic plans or meet targets or expectations ===== SIDA 23 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 23 Table 16: Condensed consolidated statement of comprehensive income: H1 2025 For the half year ended 30 June 2025 $m 2024 $m - Product Sales 26,670 24,629 - Alliance Revenue 1,293 939 Product Revenue 27,963 25,568 Collaboration Revenue 82 49 Total Revenue 28,045 25,617 Cost of sales (4,714) (4,401) Gross profit 23,331 21,216 Distribution expense (278) (267) Research and development expense (6,707) (5,791) Selling, general and administrative expense (9,356) (9,424) Other operating income and expense 192 127 Operating profit 7,182 5,861 Finance income 149 211 Finance expense (785) (856) Share of after tax losses in associates and joint ventures (17) (19) Profit before tax 6,529 5,197 Taxation (1,160) (1,089) Profit for the period 5,369 4,108 Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit pension liability (30) 101 Net (losses)/gains on equity investments measured at fair value through other comprehensive income (125) 89 Fair value movements related to own credit risk on bonds designated as fair value through profit or loss - 12 Tax on items that will not be reclassified to profit or loss (3) (27) (158) 175 Items that may be reclassified subsequently to profit or loss: Foreign exchange arising on consolidation 2,464 (554) Foreign exchange arising on designated liabilities in net investment hedges 10 (96) Fair value movements on cash flow hedges 273 (138) Fair value movements on cash flow hedges transferred to profit and loss (315) 102 Fair value movements on derivatives designated in net investment hedges (20) 45 Gains of hedging 10 14 Tax on items that may be reclassified subsequently to profit or loss (52) 38 2,370 (589) Other comprehensive income/(expense), net of tax 2,212 (414) Total comprehensive income for the period 7,581 3,694 Profit attributable to: Owners of the Parent 5,366 4,106 Non-controlling interests 3 2 5,369 4,108 Total comprehensive income attributable to: Owners of the Parent 7,574 3,692 Non-controlling interests 7 2 7,581 3,694 Earnings per share Basic earnings per $0.25 Ordinary Share $3.46 $2.65 Diluted earnings per $0.25 Ordinary Share $3.44 $2.63 Weighted average number of Ordinary Shares in issue (millions) 1,550 1,549 Diluted weighted average number of Ordinary Shares in issue (millions) 1,560 1,560 Interim financial statements ===== SIDA 24 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 24 Table 17: Condensed consolidated statement of comprehensive income: Q2 2025 For the quarter ended 30 June Unreviewed 2025 $m Unreviewed 2024 $m - Product Sales 13,795 12,452 - Alliance Revenue 654 482 Product Revenue 14,449 12,934 Collaboration Revenue 8 4 Total Revenue 14,457 12,938 Cost of sales (2,473) (2,183) Gross profit 11,984 10,755 Distribution expense (143) (132) Research and development expense (3,548) (3,008) Selling, general and administrative expense (4,864) (4,929) Other operating income and expense 79 60 Operating profit 3,508 2,746 Finance income 68 100 Finance expense (439) (443) Share of after tax losses in associates and joint ventures (10) (6) Profit before tax 3,127 2,397 Taxation (679) (469) Profit for the period 2,448 1,928 Other comprehensive income Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit pension liability (81) (43) Net (losses)/gains on equity investments measured at fair value through other comprehensive income (67) 54 Fair value movements related to own credit risk on bonds designated as fair value through profit or loss - 12 Tax on items that will not be reclassified to profit or loss 14 12 (134) 35 Items that may be reclassified subsequently to profit or loss: Foreign exchange arising on consolidation 1,312 (39) Foreign exchange arising on designated liabilities in net investment hedges (43) 2 Fair value movements on cash flow hedges 201 (52) Fair value movements on cash flow hedges transferred to profit and loss (213) 32 Fair value movements on derivatives designated in net investment hedges (10) 23 Gains/(costs) of hedging 18 (1) Tax on items that may be reclassified subsequently to profit or loss (22) 3 1,243 (32) Other comprehensive income, net of tax 1,109 3 Total comprehensive income for the period 3,557 1,931 Profit attributable to: Owners of the Parent 2,450 1,927 Non-controlling interests (2) 1 2,448 1,928 Total comprehensive income attributable to: Owners of the Parent 3,556 1,930 Non-controlling interests 1 1 3,557 1,931 Earnings per share Basic earnings per $0.25 Ordinary Share $1.58 $1.24 Diluted earnings per $0.25 Ordinary Share $1.57 $1.24 Weighted average number of Ordinary Shares in issue (millions) 1,550 1,550 Diluted weighted average number of Ordinary Shares in issue (millions) 1,559 1,560 The Q2 2025 and Q2 2024 information in respect of the three months ended 30 June 2025 and 30 June 2024 respectively included in the interim Financial Statements have not been reviewed by PricewaterhouseCoopers LLP. ===== SIDA 25 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 25 Table 18: Condensed consolidated statement of financial position Reviewed At 30 Jun 2025 Audited At 31 Dec 2024 Reviewed At 30 Jun 2024 Assets $m $m $m Non-current assets Property, plant and equipment 11,637 10,252 9,630 Right-of-use assets 1,592 1,395 1,203 Goodwill 21,222 21,025 21,060 Intangible assets 37,925 37,177 39,426 Investments in associates and joint ventures 276 268 264 Other investments 1,863 1,632 1,607 Derivative financial instruments 509 182 217 Other receivables 1,066 930 806 Income tax receivable 1,137 - - Deferred tax assets 6,256 5,347 4,734 83,483 78,208 78,947 Current assets Inventories 6,467 5,288 5,667 Trade and other receivables 14,168 12,972 11,047 Other investments 50 166 160 Derivative financial instruments 95 54 28 Income tax receivable 1,001 1,859 1,575 Intangible assets 100 - - Cash and cash equivalents 7,058 5,488 6,916 28,939 25,827 25,393 Total assets 112,422 104,035 104,340 Liabilities Current liabilities Interest-bearing loans and borrowings (6,492) (2,337) (5,067) Lease liabilities (361) (339) (292) Trade and other payables (23,986) (22,465) (20,463) Derivative financial instruments (100) (50) (51) Provisions (1,168) (1,269) (1,168) Income tax payable (1,429) (1,406) (1,525) (33,536) (27,866) (28,566) Non-current liabilities Interest-bearing loans and borrowings (24,714) (26,506) (27,225) Lease liabilities (1,272) (1,113) (949) Derivative financial instruments - (115) (61) Deferred tax liabilities (3,615) (3,305) (3,333) Retirement benefit obligations (1,418) (1,330) (1,326) Provisions (972) (921) (1,074) Income tax payable (485) (238) - Other payables (1,600) (1,770) (2,208) (34,076) (35,298) (36,176) Total liabilities (67,612) (63,164) (64,742) Net assets 44,810 40,871 39,598 Equity Share capital 388 388 388 Share premium account 35,238 35,226 35,199 Other reserves 2,070 2,012 2,078 Retained earnings 7,023 3,160 1,847 Capital and reserves attributable to equity holders of the Parent 44,719 40,786 39,512 Non-controlling interests 91 85 86 Total equity 44,810 40,871 39,598 The Condensed consolidated statements of financial position as at 30 June 2025 and 30 June 2024 have been reviewed by PricewaterhouseCoopers LLP. The Condensed consolidated statement of financial position as at 31 December 2024 has been audited by PricewaterhouseCoopers LLP. ===== SIDA 26 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 26 Table 19: Condensed consolidated statement of changes in equity Share capital Share premium account Other reserves Retained earnings Total attributable to owners of the parent Non- controlling interests Total equity $m $m $m $m $m $m $m At 1 Jan 2024 388 35,188 2,065 1,502 39,143 23 39,166 Profit for the period - - - 4,106 4,106 2 4,108 Other comprehensive expense - - - (414) (414) - (414) Transfer to other reserves - - 13 (13) - - - Transactions with owners Dividends - - - (3,052) (3,052) - (3,052) Issue of Ordinary Shares - 11 - - 11 - 11 Changes in non-controlling interests - - - - - 61 61 Share-based payments charge for the period - - - 307 307 - 307 Settlement of share plan awards - - - (589) (589) - (589) Net movement - 11 13 345 369 63 432 At 30 Jun 2024 388 35,199 2,078 1,847 39,512 86 39,598 At 1 Jan 2025 388 35,226 2,012 3,160 40,786 85 40,871 Profit for the period - - - 5,366 5,366 3 5,369 Other comprehensive income - - (34) 2,242 2,208 4 2,212 Transfer to other reserves - - 47 (47) - - - Transactions with owners Dividends - - - (3,249) (3,249) - (3,249) Issue of Ordinary Shares - 12 - - 12 - 12 Changes in non-controlling interests - - - - - (1) (1) Movement in shares held by Employee Benefit Trusts - - 45 - 45 - 45 Share-based payments charge for the period - - - 357 357 - 357 Settlement of share plan awards - - - (806) (806) - (806) Net movement - 12 58 3,863 3,933 6 3,939 At 30 June 2025 388 35,238 2,070 7,023 44,719 91 44,810 Transfer to other reserves includes $70m in respect of the opening balance on the Cash flow hedge reserve. The cash flow hedge reserve was previously disclosed within Retained earnings but from 2025 is disclosed within Other reserves. ===== SIDA 27 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 27 Table 20: Condensed consolidated statement of cash flows: H1 2025 For the half year ended 30 June 2025 $m 2024 $m Cash flows from operating activities Profit before tax 6,529 5,197 Finance income and expense 636 645 Share of after tax losses of associates and joint ventures 17 19 Depreciation, amortisation and impairment 2,673 2,534 Movement in working capital and short-term provisions (771) (584) Gains on disposal of intangible assets (87) (21) Fair value movements on contingent consideration arising from business combinations (30) 251 Non-cash and other movements 304 (550) Cash generated from operations 9,271 7,491 Interest paid (623) (583) Tax paid (1,549) (1,337) Net cash inflow from operating activities 7,099 5,571 Cash flows from investing activities Acquisition of subsidiaries, net of cash acquired - (2,771) Payment of contingent consideration from business combinations (629) (474) Purchase of property, plant and equipment (1,088) (799) Disposal of property, plant and equipment 10 53 Purchase of intangible assets (1,804) (1,474) Disposal of intangible assets 95 75 Purchase of non-current asset investments (188) (67) Disposal of non-current asset investments - 51 Movement in short-term investments, fixed deposits and other investing instruments 115 42 Payments to associates and joint ventures - (140) Disposal of investments in associates and joint ventures - 13 Interest received 128 206 Net cash outflow from investing activities (3,361) (5,285) Net cash inflow before financing activities 3,738 286 Cash flows from financing activities Proceeds from issue of share capital 12 11 Own shares purchased by Employee Benefit Trust (489) - Payments to acquire non-controlling interests (2) - Issue of loans and borrowings 9 4,976 Repayment of loans and borrowings (16) (2,643) Dividends paid (3,357) (3,050) Hedge contracts relating to dividend payments 104 (8) Repayment of obligations under leases (184) (150) Movement in short-term borrowings 1,734 2,503 Payment of Acerta Pharma share purchase liability - (833) Net cash (outflow)/inflow from financing activities (2,189) 806 Net increase in Cash and cash equivalents in the period 1,549 1,092 Cash and cash equivalents at the beginning of the period 5,429 5,637 Exchange rate effects 54 (52) Cash and cash equivalents at the end of the period 7,032 6,677 Cash and cash equivalents consist of: Cash and cash equivalents 7,058 6,916 Overdrafts (26) (239) 7,032 6,677 ===== SIDA 28 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 28 We confirm that to the best of our knowledge: – the condensed consolidated Interim Financial Statements have been prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union and UK- adopted IAS 34; – the half-yearly management report gives a true and fair view of the assets, liabilities, financial position and profit or loss of the company; – the half-yearly management report includes a fair review of the information required by: a) DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed consolidated Interim Financial Statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and b) DTR 4.2.8R of the Disclosure and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the enterprise during that period; and any changes in the related party transactions described in the last annual report that could do so. The Board The Board of Directors that served during all or part of the six month period to 30 June 2025 and their respective responsibilities can be found on the Leadership team section of astrazeneca.com. Approved by the Board and signed on its behalf by Pascal Soriot Chief Executive Officer 29 July 2025 Responsibility statement of the directors in respect of the half -yearly financial report ===== SIDA 29 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 29 Report on the Interim financial statements Our conclusion We have reviewed AstraZeneca PLC’s Interim financial statements (the “Interim financial statements”) in the H1 and Q2 2025 results of AstraZeneca PLC for the six month period ended 30 June 2025 (the “period”). Based on our review, nothing has come to our attention that causes us to believe that the Interim financial statements are not prepared, in all material respects, in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK- adopted IAS 34, and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority. The Interim financial statements comprise: – the Condensed consolidated statement of financial position as at 30 June 2025; – the Condensed consolidated statement of comprehensive income: H1 2025 for the period then ended; – the Condensed consolidated statement of changes in equity for the period then ended; – the Condensed consolidated statement of cash flows: H1 2025 for the period then ended; and – the explanatory notes to the Interim financial statements. The Interim financial statements included in the H1 and Q2 2025 results of AstraZeneca PLC have been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting' (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK- adopted IAS 34, and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority. Basis for conclusion We conducted our review in accordance with International Standard on Review Engagements (UK) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’ issued by the Financial Reporting Council for use in the United Kingdom (“ISRE (UK) 2410”). A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We have read the other information contained in the H1 and Q2 2025 results and considered whether it contains any apparent misstatements or material inconsistencies with the information in the Interim financial statements. Conclusions relating to going concern Based on our review procedures, which are less extensive than those performed in an audit as described in the Basis for conclusion section of this report, nothing has come to our attention to suggest that the directors have inappropriately adopted the going concern basis of accounting or that the directors have identified material uncertainties relating to going concern that are not appropriately disclosed. This conclusion is based on the review procedures performed in accordance with ISRE (UK) 2410. However, future events or conditions may cause the group to cease to continue as a going concern. Responsibilities for the Interim financial statements and the review Our responsibilities and those of the directors The H1 and Q2 2025 results, including the Interim financial statements, is the responsibility of, and has been approved by the directors. The directors are responsible for preparing the H1 and Q2 2025 results in accordance with the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority. In preparing the H1 and Q2 2025 results, including the Interim financial statements, the directors are responsible for assessing the group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or to cease operations, or have no realistic alternative but to do so. Our responsibility is to express a conclusion on the Interim financial statements in the H1 and Q2 2025 results based on our review. Our conclusion, including our Conclusions relating to going concern, is based on procedures that are less extensive than audit procedures, as described in the Basis for conclusion paragraph of this report. This report, including the conclusion, has been prepared for and only for the company for the purpose of complying with the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and for no other purpose. We do not, in giving this conclusion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing. PricewaterhouseCoopers LLP Chartered Accountants London 29 July 2025 Independent review report to AstraZeneca PLC ===== SIDA 30 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 30 Note 1: Basis of preparation and accounting policies These unaudited Interim financial statements for the six months ended 30 June 2025 have been prepared in accordance with International Accounting Standard 34, ‘Interim Financial Reporting’ (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK- adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom’s Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The unaudited Interim financial statements for the six months ended 30 June 2025 were approved by the Board of Directors for publication on 29 July 2025. This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2024 were prepared in accordance with UK- adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group’s published consolidated financial statements for the year ended 31 December 2024. The comparative figures for the financial year ended 31 December 2024 are not the Group’s statutory accounts for that financial year. Those accounts have been reported on by the Group’s auditors and will be delivered to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006. Product Revenue Effective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal ‘Product Revenue’ representing the summation of Product Sales and Alliance Revenue. Product Revenue and Collaboration Revenue form Total Revenue. Product Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue. Full descriptions of Product Sales, Alliance Revenue and Collaboration Revenue are included from page 152 of the Group's Annual Report and Form 20-F Information 2024. There are no changes to the Revenue accounting policy regarding the types of transactions recorded in each revenue category. The comparative period has been retrospectively adjusted to reflect the additional subtotal, resulting in total Product Revenue being reported for the half year ended 30 June 2024 of $25,568m. Going concern The Group has considerable financial resources available. As at 30 June 2025, the Group has $11.9bn in financial resources (cash and cash equivalent balances of $7.1bn and undrawn committed bank facilities of $4.9bn that are available until April 2030), with $6.9bn of borrowings due within one year. These facilities contain no financial covenants. The Group has assessed the prospects of the Group over a period longer than the required 12 months from the date of Board approval of these consolidated financial statements, with no deterioration noted requiring a further extension of this review. The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas. Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Interim financial statements. Legal proceedings The information contained in Note 5 updates the disclosures concerning legal proceedings and contingent liabilities in the Group's Annual Report and Form 20-F Information 2024. Notes to the Interim financial statements ===== SIDA 31 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 31 Note 2: Intangible assets The acquisition of EsoBiotec completed on 19 May 2025. The transaction is recorded as an asset acquisition based upon the concentration test permitted under IFRS 3 ‘Business Combinations’, with consideration and net assets acquired of $403m, which included intangible assets acquired of $426m, current payables of $29m, $4m of cash and cash equivalents and current receivables of $2m. Contingent consideration of up to $575m could be paid on achievement of regulatory milestones, those liabilities will be recorded when the relevant regulatory milestone is achieved. Note 3: Net debt Table 21: Net debt At 1 Jan 2025 Cash flow Non-cash and other Exchange movements At 30 Jun 2025 $m $m $m $m $m Non-current instalments of loans (26,506) - 2,431 (639) (24,714) Non-current instalments of leases (1,113) - (106) (53) (1,272) Total long-term debt (27,619) - 2,325 (692) (25,986) Current instalments of loans (2,007) 7 (2,461) - (4,461) Current instalments of leases (339) 217 (218) (21) (361) Commercial paper - (1,470) - - (1,470) Collateral received from derivative counterparties (181) (254) - - (435) Other short-term borrowings excluding overdrafts (90) (10) - - (100) Overdrafts (59) 34 - (1) (26) Total current debt (2,676) (1,476) (2,679) (22) (6,853) Gross borrowings (30,295) (1,476) (354) (714) (32,839) Net derivative financial instruments 71 (100) 533 - 504 Net borrowings (30,224) (1,576) 179 (714) (32,335) Cash and cash equivalents 5,488 1,515 - 55 7,058 Other investments - current 166 (115) - (1) 50 Cash and investments 5,654 1,400 - 54 7,108 Net debt (24,570) (176) 179 (660) (25,227) The table above provides an analysis of Net debt and a reconciliation of Net cash flow to the movement in Net debt. The Group monitors Net debt as part of its capital management policy as described in Note 28 of the Annual Report and Form 20-F Information 2024. Net debt is a non- GAAP financial measure. Net debt increased by $657m in the six months to 30 June 2025 to $25,227m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Non-cash movements in the period include fair value adjustments under IFRS 9 'Financial Instruments'. The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 June 2025 was $435m (31 December 2024: $181m) and the carrying value of such cash collateral posted by the Group at 30 June 2025 was $32m (31 December 2024: $129m). The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown. During the six months ended 30 June 2025, Moody’s upgraded the Group’s solicited long term credit rating to A1 from A2, which occurred during Q1 2025. The short term rating remained at P-1. There were no changes to Standard and Poor’s credit ratings (long term: A+; short term: A-1). ===== SIDA 32 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 32 Note 4: Financial Instruments As detailed in the Group's most recent annual financial statements, the principal financial instruments consist of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, trade and other payables, lease liabilities and interest-bearing loans and borrowings. The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are held at $523m (31 December 2024: $353m) and for which a fair value loss of $35m has been recognised in the six months ended 30 June 2025 (H1 2024: fair value gain of $1m). In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusted as necessary for impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains and/or losses that are presented in Net gains/(losses) on equity investments measured at fair value through other comprehensive income, in the Condensed consolidated statement of comprehensive income for the six months ended 30 June 2025 are Level 1 fair value measurements, valued based on quoted prices in active markets. Financial instruments measured at fair value include $1,880m of other investments, $5,597m held in money- market funds and $504m of derivatives as at 30 June 2025. With the exception of derivatives being Level 2 fair valued, and certain equity instruments of $523m categorised as Level 3, the aforementioned balances are Level 1 fair valued. Financial instruments measured at amortised cost include $32m of cash collateral pledged to counterparties. The total fair value of Interest-bearing loans and borrowings as at 30 June 2025, which have a carrying value of $32,839m in the Condensed consolidated statement of financial position, was $32,203m. Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues. The contingent consideration balance relating to BMS's share of the global diabetes alliance of $782m (31 December 2024: $1,309m) would increase/decrease by $78m with an increase/decrease in sales of 10%, as compared with the current estimates. Table 22: Contingent consideration 2025 2024 Diabetes alliance $m Other $m Total $m Total $m At 1 January 1,309 442 1,751 2,137 Additions through business combinations - - - 198 Settlements (518) (111) (629) (474) Revaluations (30) - (30) 251 Discount unwind 21 11 32 57 At 30 June 782 342 1,124 2,169 Note 5: Legal proceedings and contingent liabilities AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in AstraZeneca’s Annual Report and Form 20-F Information 2024 (the Disclosures). Information about the nature and facts of the cases is disclosed in accordance with IAS 37 ‘Provisions, Contingent Liabilities and Contingent Assets’. As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain. In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the expected loss. The position could change over time and the estimates that the Group made, and upon which the Group have relied in calculating these provisions are inherently imprecise. There can, therefore, be no assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of the provisions that have been booked in the accounts. The major factors causing this uncertainty are described more fully in the Disclosures and herein. AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP. ===== SIDA 33 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 33 Matters disclosed in respect of the second quarter of 2025 and to 29 July 2025 Patent litigation Legal proceedings brought against AstraZeneca Forxiga Patent Proceedings, UK Considered to be a contingent liability  In the UK, one of AstraZeneca's patents relating to Forxiga is being challenged by Generics (UK) Limited, Teva Pharmaceutical Industries Limited, and Glenmark Pharmaceuticals Europe Limited.  Trial regarding patent validity occurred in March 2025. In April 2025, the UK Patents Court held the patent invalid. AstraZeneca appealed the decision. In July 2025, the UK Court of Appeal dismissed AstraZeneca's appeal and upheld the lower court's invalidity decision. In July 2025, AstraZeneca applied for permission to appeal to the UK Supreme Court.  In March 2025 and onward, AstraZeneca applied for injunctions against generics manufacturers' at-risk sales of dapagliflozin products in the UK. AstraZeneca has obtained injunctions against generics manufacturers with UK marketing authorizations for dapagliflozin products through July 2025. In July 2025, AstraZeneca applied to the UK Supreme Court for injunctive relief. Lynparza Patent Proceedings, Canada Considered to be a contingent liability  In July 2025, AstraZeneca was served with a Notice of Allegation from Cipla Ltd. challenging a patent relating to Lynparza.  AstraZeneca is considering its next steps. Tagrisso Patent Proceedings, China Considered to be a contingent liability  In January 2025, an individual filed invalidity challenges against several Chinese patents protecting Tagrisso.  A hearing before the Chinese Patent Office was held in July 2025. AstraZeneca is awaiting a decision. Legal proceedings brought by AstraZeneca Lokelma Patent Proceedings, US Matter concluded  In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against five generic filers in the US District Court for the District of Delaware. AstraZeneca alleged that a generic version of Lokelma would infringe patents that are owned or licensed by AstraZeneca.  AstraZeneca has entered into separate settlement agreements with the five generic manufacturers which resulted in dismissal of the corresponding litigations.  This matter is now concluded. Soliris Patent Proceedings, Europe Considered to be a contingent asset  In March 2024, AstraZeneca filed motions for provisional measures against Amgen Pharmaceuticals Inc (Amgen) and Samsung Bioepis Co. Ltd. (Samsung) and their respective affiliates at the Hamburg Local Division of the Unified Patent Court (UPC) on the basis that Amgen's and Samsung's biosimilar eculizumab products infringe an AstraZeneca patent. In June 2024, the UPC denied AstraZeneca's motions. AstraZeneca appealed and in December 2024 the UPC appellate division denied AstraZeneca's appeal requesting provisional measures. In June 2025, the UPC appellate division denied AstraZeneca's request for rehearing of the appeal.  In parallel, Samsung and Amgen have filed oppositions to the patent at the European Patent Office. An oral hearing is scheduled for April 2026.  In November 2024, Amgen filed a revocation action for the patent at the UPC Central Division in Milan. A hearing is scheduled for January 2026. Soliris Patent Proceedings, Canada Considered to be a contingent asset  In May 2023, AstraZeneca initiated patent litigation in Canada alleging that Amgen Pharmaceutical Inc.'s (Amgen) biosimilar eculizumab product will infringe AstraZeneca's patents.  In September 2023, AstraZeneca initiated patent litigations in Canada alleging that Samsung Bioepis Co. Ltd.'s (Samsung) biosimilar eculizumab product will infringe AstraZeneca's patents. The filing of the litigation triggered an automatic 24-month stay of the approval of each defendant's biosimilar eculizumab product.  Trial against Amgen occurred in January 2025. In May 2025, the Canadian court found AstraZeneca's patent would be infringed and enjoined Amgen from making, constructing, using, or selling the Amgen biosimilar eculizumab product in Canada until March 2027. Amgen has appealed this decision.  In July and August 2023, in Canada, both Amgen and Samsung brought actions challenging the validity of AstraZeneca's patent relating to the use of eculizumab in treating aHUS. Trial with Amgen is scheduled for November 2025.  In June 2025, AstraZeneca and Samsung settled the Canadian eculizumab patent matters. ===== SIDA 34 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 34 Soliris Patent Proceedings, UK Considered to be a contingent asset  May 2024, AstraZeneca initiated patent infringement proceedings against Amgen Ltd. (Amgen) and Samsung Bioepis UK Limited (Samsung) in the UK High Court of Justice alleging that their respective biosimilar eculizumab products infringe an AstraZeneca patent; on the same day, Samsung initiated a revocation action for the same patent.  Trial was held in March 2025. In May 2025, the UK court issued a decision finding AstraZeneca's patent invalid and not infringed. AstraZeneca is evaluating its options. Tagrisso Patent Proceedings, Russia Considered to be a contingent asset  In August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow region (Court) against the Russian Ministry of Health (MOH) and Axelpharm LLC for improper use of AstraZeneca information in the authorisation of a generic version of Tagrisso. The suit against the MOH was dismissed in July 2024, after two appeals. The case against Axelpharm was dismissed in September 2024, and AstraZeneca has appealed.  In November 2023, Axelpharm sought a compulsory licence under a patent related to Tagrisso; the action remains pending. The Axelpharm patent on which the compulsory licensing action was based was held invalid by the Russian Patent and Trademark Office (PTO) in August 2024 following challenge by AstraZeneca. The PTO's decision was upheld in June 2025, following an appeal by Axelpharm  In July 2024, AstraZeneca filed a patent infringement claim against Axelpharm in relation to a generic version of Tagrisso. The action was stayed by the court pending resolution of the compulsory licensing action.  In August 2024, after AstraZeneca filed a complaint, the Federal Anti-Monopoly Service of Russia (FAS) initiated a case against Axelpharm and OncoTarget. In November 2024, the FAS found Axelpharm to have committed unfair competition, but not OncoTarget. Axelpharm's appeal against the FAS's finding was upheld in June 2025. AstraZeneca has appealed against this ruling. Commercial litigation Legal proceedings brought against AstraZeneca Definiens, Germany Considered to be a contingent liability  In July 2020, AstraZeneca received a notice of arbitration filed with the German Institution of Arbitration from the sellers of Definiens AG (Sellers) regarding the 2014 share purchase agreement (SPA) between AstraZeneca and the Sellers. The Sellers claim that they are owed approximately $140m in earn-outs under the SPA. In December 2023, after an arbitration hearing, the arbitration panel made a final award of $46m in favour of the Sellers.  In March 2024, AstraZeneca filed an application with the Bavarian Supreme Court (Court) to set aside the arbitration award.  In April 2025, the Court ruled in favour of AstraZeneca, annulled the arbitration award, and referred the dispute back to the same arbitration panel for a second determination.  In May 2025, the Sellers appealed the Court's decision to the German Federal Court of Justice. AstraZeneca also appealed the decision to refer the dispute back to the same arbitration panel. Seroquel XR Antitrust Litigation, US A provision has been taken  In 2019, AstraZeneca was named in several related complaints now proceeding in US District Court in Delaware (District Court), including several putative class action lawsuits that were purportedly brought on behalf of classes of direct purchasers or end payors of Seroquel XR, that allege AstraZeneca and generic drug manufacturers violated US antitrust laws when settling patent litigation related to Seroquel XR.  In July 2022, the District Court dismissed claims relating to one of the generic manufacturers while allowing claims relating to the second generic manufacturer to proceed.  In September 2024, AstraZeneca reached a settlement agreement with one of the plaintiff classes which the court approved.  In May 2025, AstraZeneca resolved the matter with all remaining plaintiffs for a total payment of $97M. The Court must approve the class-related portion of the settlement before the matter is concluded. ===== SIDA 35 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 35 Syntimmune Milestone Litigation, US Considered to be a contingent liability  In connection with AstraZeneca's acquisition of Syntimmune, Inc. (Syntimmune) in December 2020, AstraZeneca was served with a lawsuit filed by the stockholders' representative for Syntimmune in Delaware state court that alleged, among other things, breaches of the 2018 merger agreement (Merger Agreement).  The stockholders' representative alleges that AstraZeneca failed to meet its obligations under the Merger Agreement to use commercially reasonable efforts to achieve the milestones. AstraZeneca also filed a claim for breach of the representations in the Merger Agreement.  A trial was held in July 2023.  In September 2024, the court issued a partial decision, concluding that the first milestone in the amount of $130m was achieved, and that AstraZeneca had breached its contractual obligation to use commercially reasonable efforts to achieve the milestones. The court requested additional briefing regarding damages and further proceedings regarding AstraZeneca's claim for breach.  In June 2025, the court issued a further decision awarding an additional $181m in damages on its September 2024 breach determination. Additional proceedings regarding AstraZeneca's claim for breach are ongoing. Government investigations and proceedings Legal proceedings brought against AstraZeneca Texas Qui Tam, US Considered to be a contingent liability  In December 2022, AstraZeneca was served with an unsealed civil lawsuit brought by qui tam relators on behalf of the State of Texas in Texas state court, which alleges that AstraZeneca engaged in unlawful marketing practices.  In July 2025, the State of Texas sought to intervene in the matter.  Trial is scheduled for December 2025. Legal proceedings brought by AstraZeneca 340B State Litigation, US Considered to be a contingent asset  AstraZeneca has filed lawsuits against Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, Missouri, Nebraska, Utah, and West Virginia challenging the constitutionality of each state's 340B statute.  In the Arkansas matter, trial is scheduled for September 2025 and the state has moved to dismiss AstraZeneca's complaint. In the separate Arkansas administrative proceeding, the commissioner issued a cease-and-desist order in April 2025 requiring AstraZeneca to pause its 340B policy in Arkansas. AstraZeneca has appealed this decision.  In Kansas, after obtaining a stipulation from the state that AstraZeneca's policy does not violate the Kansas 340B statute, AstraZeneca agreed to dismiss its complaint.  In Louisiana, the court granted the state's motion for summary judgment. AstraZeneca has filed an appeal.  In Maryland, the state has moved to dismiss AstraZeneca's complaint and the court has denied AstraZeneca's preliminary injunction motion.  In Minnesota, the court found that the defendant government officials do not have authority to enforce the law and accordingly dismissed AstraZeneca's complaint for lack of standing.  In Missouri, the court granted in part and denied in part the state's motion to dismiss.  In Mississippi, the court denied AstraZeneca's preliminary injunction motion. Trial is scheduled for March 2026.  In Nebraska, AstraZeneca filed its complaint, and the case remains in the preliminary stages.  In Utah, the state moved to dismiss AstraZeneca's complaint. The court stayed AstraZeneca's case pending resolution of a related preliminary injunction motion.  In West Virginia, the matter is stayed pending an appeal of a related West Virginia litigation. Inflation Reduction Act Litigation, US Considered to be a contingent asset  In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS’ motions and dismissed AstraZeneca’s lawsuit.  In May 2025, the US Court of Appeals for the Third Circuit affirmed the District Court's dismissal of AstraZeneca's challenge. AstraZeneca intends to appeal. ===== SIDA 36 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 36 Other Additional government inquiries As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters. Matters disclosed in respect of the first quarter of 2025 and to 29 April 2025, for which no updates disclosed in respect of the second quarter of 2025 and to 29 July 2025 Commercial litigation Legal proceedings brought against AstraZeneca Soliris Antitrust Class Action, US Considered to be a contingent liability  In April 2025, AstraZeneca was named in a lawsuit filed in the US District Court for the District of Massachusetts alleging antitrust claims on behalf of a potential class of end payors for Soliris from March 2022.  The plaintiff alleges that AstraZeneca violated federal and state antitrust and business practices laws by obtaining improper patents for Soliris, delaying biosimilar entry and improperly extending Soliris’ market exclusivity. Viela Bio, Inc. Shareholder Litigation, US Matter concluded  In February 2023, AstraZeneca was served with a lawsuit filed in the Delaware state court against AstraZeneca and certain officers (collectively, Defendants), on behalf of a putative class of Viela Bio, Inc. (Viela) shareholders. The complaint alleged that the Defendants breached their fiduciary duty to Viela shareholders in the course of Viela’s 2021 merger with Horizon Therapeutics, plc.  In July 2024, the Court granted with prejudice AstraZeneca’s motion to dismiss.  In August 2024, plaintiffs appealed the dismissal.  In March 2025, the Delaware Supreme Court affirmed the dismissal.  This matter is now concluded. Government investigations and proceedings Legal proceedings brought against AstraZeneca Beyfortus Civil Investigative Demand, US Considered to be a contingent liability  In March 2025, AstraZeneca received a subpoena from the US Attorney’s Office seeking certain records relating to Beyfortus. The subpoena requests that the Company produce various documents from January 2020 to present, including communications related to specific batches of Beyfortus, customer complaints, and FDA inspection reports. Shenzhen City Customs Office Considered to be a contingent liability  In relation to the illegal drug importation allegations, in April 2025, AstraZeneca received a second Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $1.6m.  To the best of AstraZeneca's knowledge, the importation taxes referred to in the Appraisal Opinion relate to Enhertu.  A fine of between one and five times the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable. China Personal Information Infringement Considered to be a contingent liability  In relation to the personal information infringement allegation, in April 2025, AstraZeneca received a Notice of Transfer to the Prosecutor from the Shenzhen Bao'an District Public Security Bureau (the PSB) regarding suspected unlawful collection of personal information.  The Company has been informed that there was no illegal gain to the Company resulting from personal information infringement. ===== SIDA 37 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 37 Note 6: Analysis of Revenue and Other operating income and expense Table 23: Product Sales year-on-year analysis: H1 2025 The CER information in respect of H1 2025 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP. For the half year World US Emerging Markets Europe Established RoW ended 30 June Change Change Change Change Change $m Act % CER % $m Act % $m Act % CER % $m Act % CER % $m Act % CER % Tagrisso 3,488 9 10 1,439 12 1,008 10 13 658 5 5 383 3 3 Imfinzi 2,716 20 21 1,572 31 294 20 28 537 17 17 313 (11) (11) Calquence 1,634 8 9 1,090 4 103 36 49 368 15 15 73 12 15 Lynparza 1,564 8 9 689 14 323 1 4 425 7 6 127 1 2 Enhertu 428 72 76 - - 292 82 88 94 65 63 42 35 41 Zoladex 567 3 6 9 16 442 7 10 72 (7) (8) 44 (10) (9) Truqap 302 n/m n/m 253 80 8 n/m n/m 28 n/m n/m 13 n/m n/m Imjudo 170 25 25 111 26 12 58 68 23 43 43 24 (1) (2) Other Oncology 216 (10) (8) 4 (63) 146 (7) (5) 10 (16) (16) 56 (6) (7) Oncology 11,085 14 15 5,167 18 2,628 14 19 2,215 13 12 1,075 (1) - Farxiga 4,206 11 13 803 (7) 1,730 17 23 1,448 17 17 225 7 7 Crestor 635 8 10 24 11 547 15 17 - n/m n/m 64 (9) (8) Brilinta 520 (22) (21) 271 (23) 137 (18) (16) 107 (21) (21) 5 (39) (34) Seloken 308 (2) 2 - n/m 298 (3) 1 8 34 38 2 (9) (5) Lokelma 328 31 32 144 25 63 50 54 56 36 36 65 27 26 roxadustat 150 (8) (7) - - 150 (8) (7) - - - - - - Wainua 84 n/m n/m 82 n/m 1 - - 1 - - - - - Other CVRM 274 (27) (26) 27 (74) 138 14 16 76 (37) (37) 33 7 7 CVRM 6,505 6 7 1,351 (9) 3,064 11 15 1,696 9 9 394 6 6 Symbicort 1,438 (4) (2) 598 - 400 (11) (8) 272 (5) (5) 168 7 10 Fasenra 920 18 18 556 16 52 26 32 229 19 19 83 19 20 Breztri 583 28 29 295 31 156 19 21 87 34 34 45 34 36 Tezspire 198 99 n/m - - 16 n/m n/m 128 n/m n/m 54 61 63 Pulmicort 264 (30) (28) 4 (57) 208 (34) (32) 34 (8) (7) 18 8 11 Saphnelo 304 49 49 265 44 7 n/m n/m 21 n/m n/m 11 45 45 Airsupra 70 n/m n/m 69 n/m 1 n/m n/m - - - - - - Other R&I 158 (8) (8) 55 4 70 (18) (17) 29 (2) (3) 4 (4) - R&I 3,935 9 10 1,842 18 910 (12) (9) 800 18 17 383 19 21 Beyfortus 128 n/m n/m 102 91 - - - 24 n/m n/m 2 n/m n/m Synagis 162 (36) (33) (1) (22) 121 (8) (3) 25 (62) (60) 17 (70) (71) FluMist 10 20 16 - n/m - n/m n/m - n/m n/m 10 n/m n/m Other V&I 1 (91) (91) - - - n/m n/m 1 (91) (91) - n/m n/m V&I 301 (7) (5) 101 82 121 (7) (3) 50 (39) 37 29 (49) (50) Ultomiris 2,228 23 24 1,272 23 113 71 82 498 21 21 345 17 17 Soliris 974 (32) (30) 568 (30) 224 (12) (1) 112 (57) (57) 70 (40) (38) Strensiq 746 14 15 584 10 50 61 67 57 19 20 55 24 23 Koselugo 275 11 13 106 5 76 (9) (5) 71 58 58 22 25 25 Other Rare Disease 113 12 14 54 16 20 4 16 34 12 12 5 9 10 Rare Disease 4,336 2 3 2,584 3 483 6 16 772 (3) (3) 497 4 4 Nexium 426 (7) (5) 37 (21) 333 5 8 17 (35) (35) 39 (43) (41) Other 82 (19) (18) 3 (46) 59 (12) (11) 18 (32) (33) 2 8 7 Other Medicines 508 (9) (7) 40 (23) 392 2 4 35 (34) (34) 41 (41) (40) Total Medicines 26,670 8 10 11,085 10 7,598 8 12 5,568 8 8 2,419 2 2 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. ===== SIDA 38 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 38 Table 24: Product Sales year-on-year analysis: Q2 2025 (Unreviewed) The Q2 2025 information in respect of the three months ended 30 June 2025 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP. For the half year World US Emerging Markets Europe Established RoW ended 30 June Change Change Change Change Change $m Act % CER % $m Act % $m Act % CER % $m Act % CER % $m Act % CER % Tagrisso 1,810 13 12 761 16 489 13 15 351 8 4 209 9 5 Imfinzi 1,455 27 26 844 36 152 31 35 285 26 21 174 (5) (8) Calquence 872 10 10 583 5 49 36 43 198 19 14 42 27 28 Lynparza 838 13 11 378 18 162 6 7 229 11 7 69 5 2 Enhertu 230 81 82 - - 156 n/m n/m 51 63 56 23 24 28 Zoladex 284 4 5 4 (8) 219 9 11 38 (9) (13) 23 (9) (11) Truqap 170 84 84 142 57 6 n/m n/m 14 n/m n/m 8 n/m n/m Imjudo 89 20 18 57 17 7 93 84 12 39 35 13 - (4) Other Oncology 106 (12) (13) 1 (76) 70 (11) (10) 5 (27) (30) 30 - (5) Oncology 5,854 18 17 2,770 20 1,310 19 22 1,183 17 12 591 5 2 Farxiga 2,150 11 10 420 6 859 13 15 765 13 8 106 3 (1) Crestor 319 9 9 12 3 275 17 18 - n/m n/m 32 (10) (13) Brilinta 215 (37) (38) 99 (48) 63 (20) (20) 51 (26) (29) 2 (46) (39) Seloken 148 (2) 1 - n/m 143 (2) - 4 4 11 1 (5) (3) Lokelma 175 29 27 75 18 33 52 54 30 33 29 37 30 24 roxadustat 72 (18) (18) - - 72 (18) (18) - - - - - - Wainua 44 n/m n/m 43 n/m - - - 1 - - - - - Other CVRM 138 (27) (28) 16 (73) 67 24 24 38 (35) (37) 17 (8) (12) CVRM 3,261 3 3 665 (10) 1,512 9 11 889 5 1 195 2 (2) Symbicort 715 (1) (1) 319 7 168 (15) (14) 137 (5) (8) 91 11 11 Fasenra 502 19 18 307 14 26 33 36 125 27 22 44 20 18 Breztri 283 21 20 147 22 65 7 8 46 32 27 25 30 28 Tezspire 112 97 91 - - 9 n/m n/m 72 n/m n/m 31 60 55 Pulmicort 106 (32) (32) 1 (58) 81 (35) (36) 15 (14) (18) 9 2 2 Saphnelo 167 49 48 145 44 4 n/m n/m 12 n/m n/m 6 41 31 Airsupra 42 n/m n/m 42 n/m - n/m n/m - - - - - - Other R&I 61 (23) (24) 16 (35) 28 (25) (25) 15 2 (3) 2 (8) (7) R&I 1,988 11 10 977 18 381 (14) (13) 422 21 16 208 20 19 Beyfortus 98 n/m n/m 73 n/m - - - 24 n/m n/m 1 34 27 Synagis 49 (39) (37) - n/m 38 (7) (1) - n/m n/m 11 (68) (69) FluMist 10 n/m n/m - n/m - - - - n/m n/m 10 - - Other V&I - n/m n/m - - - - - - n/m n/m - n/m n/m V&I 157 40 42 73 n/m 38 (6) (1) 24 n/m n/m 22 (39) (40) Ultomiris 1,177 25 23 667 21 61 76 86 270 29 24 179 18 12 Soliris 530 (24) (22) 280 (30) 159 23 38 56 (52) (54) 35 (37) (38) Strensiq 395 16 15 319 12 16 65 58 31 30 26 29 27 21 Koselugo 137 20 18 52 (5) 36 51 50 37 42 37 12 28 22 Other Rare Disease 55 16 14 28 13 6 7 4 18 20 16 3 37 32 Rare Disease 2,294 7 7 1,346 3 278 37 48 412 5 1 258 7 2 Nexium 198 (10) (9) 18 (30) 157 7 9 6 (49) (55) 17 (52) (51) Other 43 (10) (11) 3 12 29 (12) (11) 10 (12) (18) 1 4 (3) Other Medicines 241 (10) (9) 21 (26) 186 4 5 16 (32) (38) 18 (50) (50) Total Medicines 13,795 11 10 5,852 12 3,705 11 13 2,946 12 8 1,292 4 1 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. ===== SIDA 39 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 39 Table 25: Alliance Revenue: H1 2025 For the half year ended 30 June 2025 $m 2024 $m Enhertu 834 683 Tezspire 285 180 Beyfortus 109 26 Datroway 14 - Other Alliance Revenue 51 50 Total 1,293 939 Table 26: Collaboration Revenue: H1 2025 For the half year ended 30 June 2025 $m 2024 $m Farxiga: sales milestones 77 49 Other Collaboration Revenue 5 - Total 82 49 Table 27: Other operating income and expense: H1 2025 For the half year ended 30 June 2025 $m 2024 $m Total 192 127 ===== SIDA 40 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 40 Financial calendar Announcement of 9M and Q3 2025 results: 6 November 2025 Announcement of FY and Q4 2025 results: 10 February 2026 Dividend payment dates Dividends are normally paid as follows: – First interim: Announced with the half year results and paid in September – Second interim: Announced with the full year results and paid in March The ex-dividend dates shown below are for ordinary shares listed on the London Stock Exchange (LSE). Dividend dates Announced Ex-dividend date (LSE) Record date Payment date FY 2025 First interim 29 Jul 2025 7 Aug 2025 8 Aug 2025 8 Sep 2025 For the ex-dividend dates of ordinary shares listed on the Stockholm Stock Exchange, and for American Depositary Receipts listed on NASDAQ, please check the notifications made by Euroclear Sweden AB, the Swedish Central Securities Depositary, and J.P. Morgan Chase Bank N.A., the US depositary. Contact details are below. Contact details For Investor Relations contacts, click here. For Media contacts, click here. Addresses for correspondence Registered office Registrar and transfer office Swedish Central Securities Depository US depositary 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA Equiniti Limited Aspect House Spencer Road Lancing West Sussex BN99 6DA Euroclear Sweden AB PO Box 191 SE-101 23 Stockholm J.P. Morgan Chase Bank N.A. EQ Shareowner Services P.O. Box 64504 St. Paul MN 55164-0504 UK UK Sweden US +44 (0) 20 3749 5000 0800 389 1580 +46 (0) 8 402 9000 +1 (888) 697 8018 (US only) +44 (0) 121 415 7033 +1 (651) 453 2128 Trademarks Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies other than AstraZeneca that appear in this document include: Beyfortus, a trademark of Sanofi Pasteur Inc.; Enhertu and Datroway, trademarks of Daiichi Sankyo; Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd (depending on geography); Synagis, owned by AstraZeneca or Sobi aka Swedish Orphan Biovitrum AB (publ). (depending on geography); and Tezspire, a trademark of Amgen, Inc. Information on or accessible through AstraZeneca's websites, including astrazeneca.com, does not form part of and is not incorporated into this announcement. Other shareholder information ===== SIDA 41 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 41 AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: – the risk of failure or delay in delivery of pipeline or launch of new medicines; – the risk of failure to meet regulatory or ethical requirements for medicine development or approval; – the risk of failures or delays in the quality or execution of the Group's commercial strategies; – the risk of pricing, affordability, access and competitive pressures; – the risk of failure to maintain supply of compliant, quality medicines; – the risk of illegal trade in the Group's medicines; – the impact of reliance on third-party goods and services; – the risk of failure in information technology or cybersecurity; – the risk of failure of critical processes; – the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives; – the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; – the risk of failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment; – the risk of the safety and efficacy of marketed medicines being questioned; – the risk of adverse outcome of litigation and/or governmental investigations; – intellectual property risks related to the Group's products; – the risk of failure to achieve strategic plans or meet targets or expectations; – the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; – the risk of failure in internal control, financial reporting or the occurrence of fraud; and – the risk of unexpected deterioration in the Group's financial position. ===== SIDA 42 ===== Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 42 1L, 2L, etc first line, second line, etc ABC advanced breast cancer aHUS atypical haemolytic uraemic syndrome AL amyloid light chain ASCO American Society of Clinical Oncology ATS American Thoracic Society BICLA British Isles Lupus Assessment Group-based Composite Lupus Assessment BRCA / m breast cancer gene / mutation BTC biliary tract cancer BTK / i bruton tyrosine kinase / inhibitor CDK4 cyclin-dependent kinase 4 CI confidence interval CHMP Committee for Medicinal Products for Human Use (EU) CKD chronic kidney disease CLL chronic lymphocytic leukaemia CN China COPD chronic obstructive pulmonary disease CSPC castration-sensitive prostate cancer CVRM Cardiovascular, Renal and Metabolism EBITDA earnings before interest, tax, depreciation and amortisation EFS event free survival EGFR / m epidermal growth factor receptor gene / mutation EGPA eosinophilic granulomatosis with polyangiitis EHA European Hematology Association EPS earnings per share ESR1 / m oestrogen receptor 1 gene / mutation EVH extravascular haemolysis FDA US Food and Drug Administration FDC fixed dose combination FLOT fluorouracil, oxaliplatin and docetaxel GAAP Generally Accepted Accounting Principles GEJ gastro oesophageal junction GI gastrointestinal gMG generalised myasthenia gravis HCC hepatocellular carcinoma HER2 / +/- /low /m human epidermal growth factor receptor 2 gene / positive / negative / low expression / gene mutant HES hyper-eosinophilic syndrome HF/ pEF / rEF heart failure / with preserved ejection fraction / with reduced ejection fraction hMPV human metapneumovirus HR / + / - hormone receptor / positive / negative HSCT-TMA hematopoietic stem cell transplantation- associated thrombotic microangiopathy ICS inhaled corticosteroid IL-5 interleukin-5 LABA long-acting beta-agonist LAMA long-acting muscarinic-agonist LDH lactic dehydrogenase MCL mantle cell lymphoma mCRPC metastatic castration-resistant prostate cancer MET mesenchymal-epithelial transition MIBC muscle-invasive bladder cancer n/m growth rate not meaningful NGP next-generation propellant NMOSD neuromyelitis optica spectrum disorder NRDL National Reimbursement Drug List NSCLC non-small cell lung cancer OS overall survival PARP poly ADP ribose polymerase pCR pathologic complete response PFS progression free survival PNH paroxysmal nocturnal haemoglobinuria R&D research and development RSV respiratory syncytial virus SCLC small cell lung cancer SG&A sales, general and administration SGLT2 sodium-glucose cotransporter 2 SLE systemic lupus erythematosus THP a treatment regimen: docetaxel, trastuzumab and pertuzumab TMA thrombotic microangiopathy Glossary